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CHAPTER 1 
 
Introduction 
 
1.1 Introduction 
 
The events of September 11th, 2001 and the anthrax attacks that followed 
over the subsequent months brought to the attention of all Americans the deadly 
mix of terrorism and advancements in microbiological techniques. In fact, it was 
proposed that a lone assailant working with as little as $2,500 worth of laboratory 
equipment could produce the high-quality anthrax that was mailed to Senators 
Tom Daschle and Patrick Leahy and multiple news organizations.1 While the 
Department of Defense has looked into better streamlining the design and 
storage of biodefense-based vaccines since 1998,2 it was the events of 2001 
coupled with the signing of the Project Bioshield Act in 2004 and the ten-fold 
increase in federal government biodefense-based spending from 2001 to 20083 
that has pushed the research field forward. Unfortunately, even with these 
positive developments, a 2007 survey revealed that a mere few hundred 
biodefense-related prophylactic and therapeutic products are being developed 
with only thirteen being in Phase 3 clinical trials at the time.4 In addition, 
biodefense vaccines that have been FDA-approved or are nearing approval have 
showed severe limitations. For example, the only anthrax vaccine licensed by the 
FDA, BioThrax®, requires a series of five doses administered at 0 and 4 weeks 
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and 6, 12 and 18 months to convey protection.5 Only after completing the 18 
month vaccine regimen is an individual considered fully protected and even then 
it is recommended that a yearly booster dose be administered to insure long-
lasting protection. Designing targeted, sustained-delivery vehicles for these 
newly developed vaccines could go a long way in creating efficacious vaccine 
systems. 
The polymeric drug delivery research field has shown great promise since 
its inception in the late 1960’s.6 Almost immediately, the importance of 
hydrolytically degradable materials that break down into non-toxic excretal or 
bioresorbable products in drug delivery became apparent.7 Controlled release of 
a variety of therapeutic and prophylactic treatments has been achieved over the 
years. These polymeric devices have been shown to deliver everything from 
cancer chemotherapeutics8 and oral insulin9 to DNA-based10 and protein-based11 
vaccines. The material properties of these carriers that make them excellent 
candidates for drug delivery include: enhanced potency, minimal toxicity, 
targeted delivery and controllable payload release. As illustrated in Fig. 1.1, 
controlled polymeric drug delivery has the potential to reduce the quantity and 
frequency of doses while maintaining appropriate systemic or local drug 
concentrations better than conventional delivery techniques. 
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Figure 1.1. Conventional (left) versus controlled (right) drug delivery. (Reprinted 
from Ref. 12.) 
 
While a wide array of polymers has been investigated for vaccine delivery 
applications, most research has focused on polyesters and polyanhydrides. 
Research has shown that both families of degradable polymers break down into 
biocompatible and bioresorbable products13,14, stabilize encapsulated 
antigens15,16, produce an adjuvant effect17,18 and maintain controlled release of 
their payload.19,20 Although both show potential, there are some key difference 
between polyanhydrides and polyesters.  Polyanhydride devices degrade layer-
by-layer leading to surface erosion where as polyesters allow high levels of water 
infiltration facilitating bulk erosion.21 The mechanism of erosion strongly affects 
the release of encapsulated material. Surface erosion allows for encapsulated 
payload to be released in concert with polymer degradation22, whereas bulk 
erosion can lead to cargo release significantly ahead of carrier degradation.23 
Also, polyanhydride degradation is highly tunable due to flexibility in choosing 
polymer chemistry.24 Polyesters possess limited potential to vary release profiles 
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by chemistry modulation.25 The freedom in choosing therapeutic-appropriate 
payload discharge allows for better tailored vaccine delivery vehicles. 
In order for a vaccine to be efficacious, it is imperative that the immune 
response be primed to the delivered antigen. In order for effective priming to be 
accomplished, antigen must be supplied to antigen presenting cells (APCs). If 
these APCs are properly activated and present the correct antigenic epitopes, an 
adaptive immune response can be mounted that will build long-term 
immunological memory.26 Vaccine-induced memory is crucial to allowing the host 
to fight and survive bacterial and viral infections that cause high morbidity or 
devastating disease in non-vaccinated individuals. Nowhere is the need for 
improved vaccines strategies more crucial than in the biodefense field. A 
particularly severe bioterrorism weapon is Yersinia pestis, the causative agent of 
plague. Not only is it responsible for three worldwide pandemics, but in the wrong 
hands, it could be used to devastate countries and kill millions of people. While 
whole cell-killed27 and attenuated-live vaccines28,29 have been studied for a long 
time, the development of recombinant protein based vaccines has had its 
successes30 and failures31. Proteins with enhanced expression during the 
quorum sensing process may lead to the identification of novel vaccine 
immunogens. Quorum sensing, a complex biological gene expression control 
system, is utilized by many bacteria like Y. pestis to activate virulence 
mechanisms once certain bacteria-friendly conditions are met.32 While this is 
designed to protect bacterial populations from immune clearance, it could be 
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exploited to develop vaccine strategies for immune response focusing to bacteria 
near virulence.  
In addition, as the field has transitioned from the use of whole cell lysates 
to recombinant proteins, the use of adjuvants, which are non-specific immune 
boosting substances, as part of the vaccine regimen is nearly ubiquitous.33 By 
choosing delivery vehicles that also function as adjuvants, a dose-sparing, 
single-dose vaccine can be designed. 
The overall objective of this research was to design novel polyanhydride 
nanoparticle-based vaccine delivery vehicles, which can function both as 
immunomodulatory biomaterials and long-term payload delivery systems. To 
accomplish this goal, two copolymers composed of three anhydride monomers 
were investigated. These copolymers are poly((1,6-bis(p-
carboxyphenoxy)hexane)-co-(sebacic acid)) (CPH:SA) and poly((1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane))-co-(1,6-bis(p-carboxyphenoxy)hexane)) 
(CPTEG:CPH) (Fig. 1.2). 
 
 
 
Figure 1.2. Chemical structures of random CPH:SA (top) and CPTEG:CPH 
(bottom) copolymers. 
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The interaction between nanoparticles and monocytes and the role polymer 
chemistry plays in mediating uptake of particles and soluble material is detailed 
in Chapter 4. An expansion of this analysis was undertaken in Chapter 5, where 
bone-marrow derived dendric cells were investigated for how they processed 
nanoparticles and what effect this had on cellular activation. As biodefense is 
vitally important to our homeland security, the potential of nanoparticles as 
vaccine delivery vehicles that protect against pneumonic plague was investigated 
in Chapter 6. Lastly, knowledge gained from these experiments will be utilized to 
optimize nanoparticle-based vaccines against an array of diseases as well as 
develop novel nanoparticle-based platforms to address the limitations of current 
systems (Chapter 7). 
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CHAPTER 2 
 
Literature Review 
 
2.1 Summary 
 
 Particle-based drug carriers can be composed of a number of different 
polymers or biologically-derived materials. Due to their biocompatible, 
bioresorbable and non-toxic properties, degradable polymers are excellent 
candidates for therapeutic and prophylactic medicinal strategies. In addition, 
these biomaterials can be tailored to meet treatment requirements, including 
controlled release rate and targeted delivery. Section 2.2 outlines the manner in 
which vaccines initiate an immune response and convey immunity. The capacity 
for polymeric carriers to function as vaccine delivery systems will be discussed in 
Section 2.3. Different polymer families and tailoring initiated immune responses 
will be explored. Section 2.4 overviews an especially insidious bacterial species, 
Yersinia pestis.  The causative agent of plague will be explored from historical 
and treatment perspectives. 
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2.2 Vaccine Delivery Systems 
 
2.2.1 Introduction 
 
 Over the past 200 years, the advancement of vaccines is one of 
humankind’s greatest achievements. Since Edward Jenner gave cowpox pus to 
people, conveying cross reactive protection against small pox, there has been 
worldwide eradication of small pox and elimination of polio from the developed 
world as well as near eradication of other deadly diseases like diphtheria.1,2 
Despite advances, there still exist grand challenges in the design of efficacious 
vaccination strategies. One sobering fact is that the World Health Organization 
(WHO) estimates that 1 in 7 global childhood deaths (1.4 million in 2002) is 
caused by diseases we have vaccines for.3 In developing countries this mortality 
rate is even higher. Development of vaccine adjuvant and delivery systems could 
lead to single dose vaccines. The use of polymeric vaccine carriers that function 
as adjuvants may be one the best options to solving this global issue. In order to 
develop complex, multi-disciplinary research-based solutions, one must 
understand how the immune response functions, how vaccines stimulate that 
response to convey protection and the currently available polymeric delivery 
systems. 
 
2.2.2 Immune Response to a Foreign Substance 
 
 In order to fabricate novel vaccines strategies, an overview of how the 
immune system functions is essential. The immune response is composed of a 
complex network of heavily regulated cell processes and interactions that are 
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interrelated. This network is composed of two linked systems called the innate 
and adaptive immune systems.4 
 
2.2.2.1 Innate Immune Response 
 
 The innate immune system is involved in surveillance and detection of 
foreign invaders. Common components of this response are phagocytic cells, 
Natural Killer (NK) cells, γδ T cells, anti-microbial peptides and the complement 
system.5 First detailed by Drs. Charles Janeway and Ruslan Medzhitov, the 
innate immune system uses a relatively small set of systems to identify foreign 
bodies. The bacterial associated components identified by innate immunity are 
called pathogen-associated molecular patterns (PAMPs).6 PAMPs are relatively 
conserved across bacteria and are recognized by pattern recognition receptors 
(PRRs) on phagocytic cells. Multiple PRRs exist, including mannose and 
scavenger receptors, but receptors of particular importance are the Toll-like 
receptors (TLRs).  TLRs allow for a critical phagocytic and antigen presenting cell 
(APC), the dendritic cell (DC), to recognize a group of common microbial ligands 
(e.g., unmethylated bacterial DNA (CpG) and lipopolysaccharide (LPS)).5 
Stimulation of TLRs causes a cascade down a signaling pathway ultimately 
leading to the activation of transcription factors necessary to cause cell 
maturation, migration and antigen presentation.7 DCs are found in all body 
tissues and are the primary cell type that initiates and regulates the adaptive 
immune response.8 There are three ways by which DCs can acquire antigen to 
present to the adaptive immune response. This can be accomplished by 
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phagocytosis (i.e., internalization of solid particles into vesicles) of bacteria, 
particles, or cellular debris; macropinocytosis, “cellular drinking”, of soluble 
material; and triggered endocytic uptake through mannose, complement or Fc 
receptor activation. Upon activation by antigen internalization and co-stimulation 
through TLRs or cytokines, which are chemical communication signals, DCs 
mature and are able to migrate to the draining lymph node. Maturation causes 
DCs to loses their phagocytic capability and drastically increase the surface 
expression of migratory molecules like CCR7 and DC-SIGN and stimulation 
molecules like CD40, CD80, CD86 and MHC I/II. Peptide fragments (8 to 17 
amino acids in length), called epitopes, of processed antigen are transported to 
major histocompatibility complexes I (MHC I) or II (MHC II) to allow for T cell 
recognition and activation.7,9 Antigens processed by internalization through 
phagocytosis go through the exogenous pathway in which phagosomes merge 
with lysosomes to create a proteolytic environment used to degrade antigens. 
Peptides generated from this method are able to be effectively loaded into MHC 
II and presented on the cell surface. Antigens found within the cytosol of the cell 
are degraded by proteosomes and chaperon proteins (TAPs) transport these 
peptides into the endoplasmic reticulum (ER) where they can be loaded into 
MHC I and trafficked to the cell surface for presentation. This is referred to as the 
endogenous pathway. Fig. 2.1 shows the two methods of antigen processing. 
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Figure 2.1. Exogenous (top) and endogenous (bottom) antigen presentation 
pathways. External antigen is trafficked by vesicles to mediate degradation, 
loading of MHC II and presentation on the cell surface. Internal antigen (e.g. viral 
or intracellular bacteria) is degraded, trafficked to the ER, loaded into MHC I and 
presented on the cell surface. 
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After DCs have successfully migrated to the draining lymph node and presented 
antigen, they are able to interact with T cells and bridge innate and adaptive 
immune responses. 
 
2.2.2.2 Adaptive Immune Response 
 
 The adaptive immune response is traditionally considered to have two 
branches: cell-mediated immunity (CMI) and humoral immunity. There are two 
other arms that play a role in the overall immune response, the Th17 response 
and the T regulatory response. The distinction of which response is dominant 
depends on a multitude of factors initialized by the DC to CD4+ T helper cell 
interaction. CD4+ T cells are classified as Th1, Th2, Th17 or Treg.10-12 A Th1 
immune response is characterized by the production of IFN-γ and TNF-β 
cytokines and IgG2a/c antibodies and normally associated with activated 
macrophages and delayed-type hypersensitivity of CMI.278 A Th2 immune 
response is characterized by the production of IL-4, IL-5, IL-10 and IL-13 and the 
secretion of IgG1 and IgE antibodies.13 Th1-type immune responses are 
generally directed at intracellular pathogen like viruses and intracellular bacteria 
(e.g., Brucella abortus) whereas Th2-type immune responses are generally 
directed at extracellular bacteria in which antibodies can be used to neutralize 
toxins and bacterial adhesion.14 Th17 responses are considered inflammatory, 
but their role in vaccinology is unknown.10 This response is marked by a 
production of IL-17 and has been thought to be protective during acute 
inflammation, but is also associated with chronic inflammatory disease. 
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It should be noted that these responses often act in concert to clear 
infection. There often does seems to be one dominant response and if effective 
follows the intracellular (Th1) versus extracellular (Th2) argument. DCs assist in 
CD4+ T cell differentiation by the secretion of some of the cytokines mentioned 
above in addition to the presentation of antigen. Activated DCs produce TNF-α, 
IL-1β, IL-6, IL-8, IL-12 and IL-10.  The cytokine profile secreted directly affects 
the delineation of CD4+ T cells. Also, co-stimulation (CD40, CD80 and CD86) is 
important. If antigen presentation occurs, but co-stimulatory markers are absent, 
then the DCs can induce ineffective T cell activaton like anergy (tolerance).15 Fig. 
2.2 provides an overview of the interaction between DCs and CD4+ T cells. 
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Figure 2.2. Multiple signals from DCs influence the differentiation of naïve T 
cells. The MHC to T cell receptor, co-stimulation and cytokine signaling all direct 
this response. DC cytokine secretion of IL-12 indicates a push towards Th1 and 
and IL-4 results in Th2.  In response, Th1 cells produce IFN-γ and Th2 cells 
produce IL-4, IL-5 and IL-10. 
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2.2.3 Vaccines 
 
 Vaccines function best when they mimic the immune response that would 
be generated if the disease had been contracted. In order to achieve this goal, 
some portion of the disease causing agent is given, often with a non-specific 
immune boosting substance called an adjuvant. Typical vaccine regimens 
employ an initial dose followed by two to three booster doses. The multiple doses 
allow for high immunogen quantities to be exposed to the immune system at 
different times. The first dose initiates the response of DCs and naïve immune 
cells (primary response) with the following doses activating memory immune 
cells characterized by a more robust and speedier response (secondary 
response).7 Most vaccines induce protection through neutralizing antibodies 
instead of CMI induction.16 Vaccines can be classified into two categories, whole 
cell and subunit. 
 
2.2.3.1 Whole Cell Vaccines 
 
 Outside of natural infections, vaccines possessing modified organisms 
induce the most potent and long lasting immune response in the host. The two 
types of whole cell vaccines used are live attenuated and whole killed. 
 Live attenuated vaccination requires the fewest number of doses, can 
confer lifelong immunity, and requires no adjuvants.17 Since these vaccines are 
composed of living organisms they are able to replicate and cause a mild, limited 
infection with the natural release of microbial compounds that synergistically 
induce the host response almost identically to natural infection. With live 
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vaccination, attenuation is required. This is often accomplished by repetitive 
passage (at least 10 times) in an animal host or in vitro to isolate naturally 
occurring attenuated genetic mutants. Recent advancements in microbiology 
now allow for known induction of mutations through genetic recombineering 
easing the attenuation process and making it much safer since specific virulence 
attributes can be knocked out at the genetic level.18 Sometimes cross reactivity of 
two similar microorganisms that produce similar or identical epitopes can be used 
in vaccination. Edward Jenner’s original small pox vaccine contained cow pox 
puss that had enough similarity to small pox that it conveyed protection while 
only giving the host a mild infection.19 While live attenuated vaccines have many 
beneficial properties, there are a number of issues with their use. When working 
with a live organism, there is a possibility for it to persist in the host, revert back 
to a pathogenic strain or induce disease in immunocompromised individuals. If 
persistence occurs then there is a high likelihood that the disease can spread 
and infect non-vaccinated people. In addition, live vaccines have serious 
potential to cause side-effects ranging from injection site inflammation to 
systemic disease. Finally, many diagnostic tests cannot identify differences 
between persistent avirulent microorganisms given by vaccination and naturally 
occurring infections.20 These factors limit the potential of live attenuated 
vaccines. 
 Another vaccination strategy is to use whole-killed vaccines. 
Microorganisms are treated with chemicals or heat to kill them while preserving 
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their cellular integrity. Whole-killed vaccines can be potent inducers of humoral 
immunity because most of the virulence factors and important epitopes are still 
present.17 These vaccines cannot replicate so there is no risk of persistent 
infection, reversion to virulence, or spread of disease. Also, whole killed vaccines 
are more stable and usually very cost effective. However, killed vaccines often 
require multiple doses and rarely induce strong CMI responses. Adverse side 
effects are common ranging from severe pain to redness and swelling due to the 
presence of microbial stimulants like LPS and other TLR ligands.21,22 When using 
either type of whole cell vaccine, the significant consequences can outweigh the 
benefits. 
 
2.2.3.2 Subunit Vaccines 
 
 Subunit vaccines contain only a portion of the organism being vaccinated 
against. The most common subunit vaccines are composed of toxoids, which are 
inactive bacterial toxins. Two common vaccines are formaldehyde-inactivated 
diphtheria and tetanus toxoids. Other subunit vaccines are protein- and 
carbohydrate-based. Currently, vaccines against influenza virus (hemaglutinin-
binding protein) and meningitis (polysaccharide capsule) are used.23,24 A final 
group of subunit vaccines is centered on the delivery of pathogenic DNA. DNA 
coding for a target epitope is delivered using a viral vector or DNA-containing 
particulates to DCs.23,25 Host cells express the foreign epitope and it is able to be 
presented in the context of both MHC I and II allowing for both humoral and 
cellular immunity.7 While DNA vaccines have yet to be FDA approved, there are 
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many currently in phase I, II and III human trials.26 Subunit vaccines have several 
advantages over whole cell vaccines. By using specific, protective epitopes in 
subunit vaccines, nearly all side effects are eliminated since the microbial 
components that trigger strong innate responses are no longer delivered to the 
host.  This allows for subunit vaccines to be considered extremely safe and new 
technologies have made them inexpensive to produce. The decrease in non-
specific response has its downside. These immunogens tend to be very weakly 
immunogenic and require multiple doses to convey protection.27 In order to 
enhance subunit vaccines, the delivery of adjuvants (e.g., monophosphoryl lipid 
A – MPLA) is necessary. While subunit vaccines can induce high antibody titers, 
they rarely induce protective T cell responses.  In order to overcome these 
issues, the development of specialized adjuvants is necessary. 
 
2.3 Degradable Polymers as Vaccine Adjuvants 
 
2.3.1 Introduction 
 
 Adjuvants are immunoenhancing materials that typically have three major 
functions: 1) allow for slow release of the antigen; 2) facilitate antigen targeting to 
antigen presenting cells (APCs) and promote phagocytosis; 3) modulate and 
enhance the immune response.28-30 It is also possible that adjuvants provide a 
danger signal to the immune system that mimics infection and enhances the 
immune response to the vaccine.31 
 Slow antigen release can be accomplished by entrapping antigen in a 
poorly eroding substance which can act as a depot for vaccine delivery.  The use 
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of alum, a combination of aluminum phosphate and aluminum hydroxide, is the 
most commonly used adjuvant in human medicine.  Alum makes a gel-like matrix 
that allows for a delayed release of antigen. Recently, oil adjuvants like MF59 
(squaline oil emulsion with muramyl tripeptide) have been shown to have 
beneficial adjuvant behavior with satisfactory safety making them potential 
candidates for human use.32,33 Small particles composed of stabilized lipids, 
phospholipids, or proteins (e.g. virosomes and liposomes) allow for gradual 
release by incorporating antigens into their backbones. Another approach is to 
use degradable polymer microparticles (>1 µm) or nanoparticles (<1 µm) with 
encapsulated antigen to provide sustained release. Thus, many different vehicles 
can be used to provide antigen depots. 
 Enhancement of the immune response by targeted delivery to or activation 
of APCs is another role of adjuvants. This can be accomplished by properties of 
the antigen, facets of the carrier, inclusion of immunostimulatory molecules or 
some combination thereof. Many toxins (e.g. pertussis and cholera toxins) 
actually have high binding selectivity that facilitate their uptake by APCs.31,34 
While these make great vaccines, their overwhelming stimulation of an anti-toxin 
immune response may overshadow the response to the antigen of interest 
making them less than ideal adjuvants.31 Other bacterially-derived 
immunostimulants like LPS (a surface carbohydrate from gram-negative bacteria) 
have been shown to activate NF-κB by CD14 and TLR4 causing the 
overwhelming production of pro-inflammatory cytokines.32,35 The response is so 
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strong in humans that LPS cannot be used in human vaccine preparations 
leaving few options for adjuvants that can safely enhance APC responses. 
 Immune modulation is influenced by a number of characteristics of the 
adjuvant/antigen delivery system.36,37 These include, but are not limited to, 
delivery route, antigen dose, duration of antigen delivery, number of 
immunizations, co-stimulatory molecule inclusion, and delivery system. The 
compilation of these effects results in the overall immune bias (Th1, Th2 or a 
balance) of the vaccine. The clear role of the vaccinologist is to exploit these 
factors to induce an immune response that will best mimic disease and therefore 
convey protection. Currently, the FDA approved adjuvants, alum and MF59, have 
shown limited ability to induce a Th1 type immune response that may be helpful 
in preventing some diseases.32,38 In addition, oil-based liposomal adjuvants that 
do produce a Th1 dominant response induce severe side-effects including 
inflammation, tissue reactivity, and even granuloma formation.39 With these 
limitations, a vaccine delivery system that provides sustained payload delivery, 
facilitates APC activation, and possesses tunable immunomodulatory properties 
would be highly desirable. Degradable polymers hold the potential to meet all of 
these needs. 
 
2.3.2 Polymers 
 
 In order to overcome many of the limitations in vaccine design, polymeric 
materials have been studied. Polymers are materials that contain a large number 
of repeating units called monomers. The chemical structure of monomers and 
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their linkers as well as the number of monomers covalently linked together 
dictate mechanical, thermal, and processability parameters of the material. 
Polymers like DNA, proteins and polysaccharides have always been present in 
nature. Over the past 100 years, synthetically derived polymers have given rise 
to a wide range of materials from plastic beverage containers to automotive 
bodies. The development of polymers for use in biomedical applications has had 
an overwhelming effect on the improvement of medical care. From maintaining 
product sterility to disposable syringes, polymers have changed the face of 
medicine. In addition to medical products, polymers have more recently been 
used as part of the therapeutic solution. In the 1960’s, Edward Schmitt and 
Rocco Polistina recognized the potential for degradable polymer fibers as 
surgical sutures and biomedical implants.40-42 Since then polymeric biomaterials 
have been incorporated into a wide range of therapies from the delivery of 
chemotherapeutics to tissue engineering scaffolds. For application in vaccine 
delivery, the capacity for polymeric materials to be biocompatible and excretal is 
desirable. Degradable polymers best fit these requirements. 
 Degradable polymers possess a chemical bond in their structure that can 
be cleaved. This bond is hydrolytically labile in which the presence of water 
breaks the bond adding a hydrogen atom to one product and an hydroxyl group 
to the other product as seen in Fig. 2.3. 
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Figure 2.3. The hydrolytically sensitive bond X-Y is cleaved by a water molecule 
yielding the products of X-H and HO-Y. 
 
Since each degradable polymer contains a large number of these bonds, the 
polymer is able to maintain many impressive physical properties (mechanical 
strength, processibility, etc.) while having degradation products that are 
excretable or bioresorbable. Polymers are classified by their chemistry with each 
family possessing unique characteristics. Figure 2.4 overviews the five 
degradable polymeric families (polyesters, acid-catalyzed polymers, 
polyanhydrides, polyethers, and other polymers) that will be discussed in this 
review. 
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Figure 2.4. Chemical structures of typical degradable polymers used in vaccine 
delivery. 
 
2.3.2.1 Polyesters 
 
 Biomedical applications of polyesters have been known for over 40 years. 
Polyesters are commercially available and FDA-approved for human use making 
them potentially useful biomaterials. One of their greatest properties is their low 
cytotoxicity which is attributable to the fact that they degrade into cellular 
metabolites that are easily uptaken and processed by cells.43,44 Degradable 
polyesters that have potential for vaccine delivery applications include poly(lactic 
acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyric acid) 
(P3HB), poly(4-hydroxybutyric acid) (P4HB) and poly(ε-caprolactone) (PCL) (Fig. 
2.5). 
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Figure 2.5. Chemical structures for degradable polyesters. 
 
Extensive research has been published on PLA45-51 and PLGA48-58 systems in 
drug delivery. They have been used for the delivery of everything from 
chemotherapeutics to vaccines. Poly(glycolic acid) (PGA) by itself has limited 
vaccine delivery capabilities because it is so hydrophilic it releases payload too 
rapidly and it is difficult to process by typical polymer solvents. Instead PGA has 
mostly been used in degradable sutures.59-63 P3HB and P4HB have been studied 
for their drug delivery potential,64-68 but so far their rapid release69,70 (almost all 
payload released within 24 hours), very slow polymer degradation71,72 (in vitro 
and in vivo polymer weight loss between 5% and 15% at 6 months) and 
extensive initiation of inflammatory responses73,74 have made them poor 
candidates for vaccine applications. PCL has been studied more extensively than 
PHB75-87 and is FDA-approved for drug delivery and sutures. However, PCL has 
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been shown to undergo extremely slow degradation75,76,83-85 (in vitro and in vivo 
polymer weight loss of between 14 and 20% around 1 year), release payload 
with high burst (40 – 70%) followed by very slow remaining extended release, 
and possess agent-dependent loading efficiency77-80,82,86,87 (14 – 70%) making it 
questionable for vaccine delivery applications. 
For polyesters, as well as other degradable polymers, the erosion 
mechanism of the material is of significant importance. von Burkersroda et al.88 
provide an overview of the kinetics that dictate whether a degradable polymer will 
undergo surface, bulk, or a combined erosion profiled. Essentially the erosion 
mechanism depends on the magnitude of water diffusion into the device 
compared to the rate at which the material undergoes dissolution. For 
degradable polymers, dissolution is heavily dependent on polymeric bond 
hydration. Fig. 2.6 illustrates the differences in these mechanisms. 
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Figure 2.6. Schematic comparing bulk and surface erosion. In bulk erosion (top), 
water penetrates the device quickly allowing for the dissolution of encapsulated 
material almost exclusively by diffusion. In surface erosion (bottom), water 
cannot penetrate the device and must force dissolution at the surface to degrade 
the material layer-by-layer. 
 
Bulk erosion is characterized by a diffusion dependent release of payload since 
water will reach the encapsulated material much more quickly than the 
degradation and erosion of the polymeric device. In addition, once water 
infiltration has occurred, all hydrolytically labile bonds can be attacked 
simultaneously throughout the material. These types of materials tend to fissure 
and break into smaller subunits before completing degradation. In contrast, when 
water diffuses slowly compared to the rate of erosion, the material is said to be 
surface eroding. These devices require the degradation of the surface polymer 
and dissolution of the resulting monomer to allow for encapsulated payload 
release. 
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 Within bulk erosion there exist two erosion profiles, fast degrading and 
slow degrading. The differences are highlighted in Fig. 2.7. 
 
 
 
Figure 2.7. Schematic comparing bulk eroding systems possessing fast and slow 
polymeric degradation. In fast degrading systems (top), while payload release is 
still a function of diffusion, the material degrades and breaks apart rather quickly 
after release. In slow degrading systems (bottom), even though water has 
diffused through the bulk and released encapsulated materials, the device’s 
degradation is very slow. 
 
When degradation is quick, the device can be broken apart and digested or 
excreted by the body. This is desirable since payload has already been released 
and the function of the delivery device has finished. When degradation is slow, 
the device is able to persist. In most applications this behavior is unwanted since 
it can lead to inflammation or even a granulomatous response in which the 
biomaterial is coated in immune cells.89 
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 All polyesters undergo bulk erosion due to the stability of ester bonds, but 
the degradation of these bonds is dependent on the chemistry of the backbone 
between bonds. For PGA, the single carbon chain allows for the polymer to be 
very hydrophilic.  Even though PLA has only a two carbon chain backbone, its 
degradation is significantly slower. For PGA, PLA and PLGA, the degradation is 
quick enough for the polymer to be considered a fast degrading, bulk eroding 
material. In the cases of P3HB, P4HB and PCL, the polyester device can persist 
for years with little degradation. In nearly all examples of biomaterial use, this is 
an undesirable property and one of the major reasons these polymers have 
yielded little potential as vaccine delivery vehicles. 
 Even with the extensive use of polyesters in drug delivery applications, 
there still exist significant shortcomings with their use. The biggest issues are the 
limited flexibility in tuning payload release, the formation of low pH 
microenvironments, and the constant moisture exposure of payload. Since PLA 
and PLGA are the only suitable polyester vaccine delivery options as of now, 
there is a significant lack of control in payload release. While the lactic acid 
component of PLGA can be easily modulated between 50% and 100%, the 
release profiles of encapsulated material do not significantly change.90-92 Coating 
the surface of devices90,93 has been used to overcome this issue, but changing 
surface chemistry could drastically modulate function and interaction with the 
host and host cells. 
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Another issue with polyesters is that when they degrade, their monomers 
(lactic acid and glycolic acid) significantly decrease the pH of their environment to 
as low as 1.5.94,95 Many drugs can be significantly affected by low pH, especially 
recombinant protein and subunit based vaccines (e.g., tetanus toxoid and 
diphtheria toxoid).44,96,97 Also, the bulk erosion of polyesters allows for significant 
residence time with water for encapsulated materials. These factors combine to 
allow for sensitive amino acids like aspartic acid to hydrolyze very quickly98 and 
proteins like insulin and uterocalin to aggregate, hydrolyze, and change 
conformation.99-101 In order to neutralize monomer acidity, the incorporation of 
bases (Mg(OH)2 and MgCO3) into PLGA has been proposed.102,103 While the 
acidity was reduced, the requirement of multiple compounds (stabilizers, anti-
acids, etc.) in addition to desired payload could modulate release profiles and 
decrease encapsulation efficiency. While polyesters have been extensively used 
in drug and vaccine delivery, they possess significant limitations that must be 
accounted for in order to improve their function. 
 
2.3.2.2 Acid-Catalyzed Polymers 
 
 The need for surface degrading polymers for drug delivery led Dr. Joseph 
Heller to the discovery of acid-catalyzed polymers.104-109 Acid-catalyzed polymers 
used in drug delivery have focused on the potential of polyacetals, polyketals and 
polyorthoesters (Fig. 2.8). 
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Figure 2.8. Chemical structures for acid-catalyzed polymers. 
 
 Non-degradable polyacetals have been used biomedically as fracture 
stabilizers and prosthetic materials (Delrin®) for over 30 years.110-114 Lately, the 
use of acid-catalyzed degradable polyacetals for drug delivery has been more 
extensively investigated.115-120 The approaches for therapeutic delivery being 
explored with polyacetals are polymer conjugation115-117, thermoresponsive 
gels118 and microparticles.119,120 In each study, drug was released much more 
significantly when pH was lowered from normal body pH (7.4) to between 5 and 
5.5. When conjugated poly(ethylene glycol) (PEG) is incorporated into the 
polyacetal backbone, the polymer is hydrophilic and persists without cellular 
uptake leading to longer, sustained chemotherapeutic delivery.115 In addition, 
polyacetal microparticles were able to be extensively uptake by macrophages 
when the correct backbone chemistry is chosen.120 These early experiments 
provide evidence that polyacetals could be used to selectively deliver payload. 
 Similar to polyacetals, drug delivery with polyketals is an emerging field of 
research.121-125 Approaches for drug delivery have used nanoparticles and 
microparticles (200 nm to 5 µm). The design of these particles has been for the 
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delivery of antigens and therapeutics to macrophages as vaccines125 or in the 
treatment of acute respiratory diseases124, respectively. While early results are 
promising, more research is necessary to determine the capabilities of these 
materials. 
 While polyorthoesters126,127 have been studied for much longer than 
polyacetals and polyketals, research in drug delivery did not intensify until 
polymer synthesis techniques improved in the early 1990’s. Drug delivery with 
polyorthoesters now includes cancer chemotherapeutics128-130, periodontal 
therapies131,132, anti-inflammatory drugs133, intraocular delivery134,135, 
anasthetics136, proteins137 and DNA delivery.138 The two most commonly used 
polyorthoester-based devices are implants and microparticles. Currently, release 
from these polymers, even in normal body pH conditions is not long enough for 
vaccine applications, but new polyorthoesters are being synthesized, like 
poly(ortho ester amides)139, which may lead to the development of more gradual 
payload-releasing polymers. 
 While less attention has been given to acid-catalyzed polymers than other 
families of polymers, their properties provide unique opportunities for their 
application in vaccine delivery. Antigen presenting cells (APCs) break down 
material internalized by endocytosis with the assistance of lysosomal fusion.140 
The lysosome possesses a number of tools used to degrade and process 
material including radical oxygen and nitrogen intermediates, enzymes and 
proton pumps. The proton pumps are of particular interest since they are able to 
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drastically reduce vesicle pH from 7.4 to between 5 and 5.5.140 Acid-catalyzed 
polymers can utilize this behavior to improve vaccine delivery. By maintaining 
polymer structure in normal physiological pH and rapidly degrading in lysosomal 
pH, acid-catalyzed polymer vaccine delivery vehicles can direct their payload 
release within APCs. In addition, the degradation products of this family of 
polymers have been shown to not induce microenvironment pH changes and are 
very biocompatible.120 As the field of acid-catalyzed polymers matures, vaccine 
delivery applications may be further developed. 
 
2.3.2.3 Polyanhydrides 
 
 Since initial research showed polyanhydrides to possess good 
biocompatibility and drug delivery potential, significant research has been 
conducted with these materials.141-155 The general chemical structure for a 
polyanhydride is shown in Fig. 2.9. 
 
 
 
Figure 2.9. Chemical structure of a polyanhydride. 
 
Research in polyanhydride drug delivery spans treatments for glaucoma156,157, 
Alzheimer’s disease158,159, cartilage repair160, brain cancer161,162, 
osteomyletis163,164, seizure suppression165 and prolonged delivery of 
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anasthetic166, chemotherapeutics167,168, insulin169, analgesic170, antibiotic171 and 
proteins.172 The reason polyanhydrides are able to be used in the delivery of 
such a large number of therapeutics for a variety of diseases is due to their 
unique material properties not possessed by most other polymeric families. von 
Burkersroda et al.88 state that the half-life of anhydride degradation is two orders 
of magnitude greater than polyketals and polyorthoesters, five orders of 
magnitude greater than polyacetals and six orders of magnitude greater than 
polyesters. This indicates that anhydrides are very susceptible to hydrolytic 
degradation. By tuning the degree of hydrophobicity of the backbone chemistry, 
polyanhydride devices can be modulated from fast degrading (10 days) to very 
slow degrading (over 1 year). With most backbone chemistries (aliphatic or 
aromatic hydrocarbons), the devices act as surface degrading materials. The 
incorporation of hydrophilic groups (e.g., ethylene glycol) shifts the degradation 
towards a combination of bulk and surface erosion. In addition, the monomers 
released from polyanhydride degradation are not nearly as acidic (4.2 – 7.5) as 
those in polyester degradation (1.5 – 3.6).152,173 The milder pH microenvironment 
combined with surface erosion preventing hydrolytic aggregation make 
polyanhydrides promising materials for recombinant protein and subunit vaccine 
delivery. 
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2.3.2.4 Polyethers 
 
 Synthetically derived and naturally-inspired polyethers have been used in 
polymeric drug delivery for nearly 30 years.174-176 The most commonly used 
polyethers for drug delivery are shown in Fig. 2.10. 
 
 
 
Figure 2.10. Chemical structures of polyethers. 
 
Poly(ethylene glycol) (PEG) and poly(propylene glycol) (PPG) have been used in 
numerous biomaterials from triblock Pluronic ([PEG]n-[PPG]m-[PEG]n) to being 
used in concordance with many of the previously described polymer groups. 
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Pluronic is of particular importance since the hydrophobic PPG and hydrophilic 
PEG form very small micelle particles (~ 10 to 100 nm in diameter)177 by self 
assembly in water. This amphiphilic material allows for high payload loading (20 
to 30 wt%)178 of hydrophobic drugs into the core while possessing a hydrophilic 
shell making the particles easy to administer. Also, amphiphilicity allows for the 
particle to interact with biological membranes and hydrophobic surfaces. Other 
polymeric groups have benefited from the research of PEG. Drug devices 
fabricated out of polyesters, polyanhydrides and acid-catalyzed polymers coated 
with PEG have been shown to possess a ”stealth” effect in which the hydrophilic 
PEG opposes interactions with the host, especially phagocytosis and cellular 
adhesion.179-181 PEG has also been incorporated into the backbone of these 
polymers to facilitate desired characteristics like amphiphilicity in 
polyanhydrides182,183, acid catalyzed polymers118,119,184 and PCL.185,186 
 Naturally derived polymers like chitosan and hyaluronic acid have shown 
promise as drug delivery vehicles as well.187-190 These polymers are used in a 
similar fashion as the synthetic polyethers. In drug delivery they have been used 
as hydrogels187,188, microparticles190, as stealth or Trojan coatings189 or 
polymerized with other polymers of interest. 
 Polyethers do not readily undergo hydrolytic degradation since the ether 
bond is very stable in water. Instead, polyethers can be either degraded by 
enzymes or through oxidation or can be dissociated from the device and 
excreted. While there are specific enzymes for chitosan (papain) and hyaluronic 
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acid (hyaluronidase), polyether degradation has only been extensively reported 
in bacterial cultures.191,192 The use of high molecular weight PEG is of most 
concern since slow in vivo degradation could lead to significant accumulation. It 
appears that the use of polyesters in combination with other biomaterials or in 
low molecular weight forms may be safest. 
 
2.3.2.5 Other Polymers 
 While the four groups introduced so far make up the majority of polymers 
used in degradable drug delivery, there are others polymers currently being 
studied. Some of the most promising are presented in Fig. 2.11. 
 
 
Figure 2.11. Chemical structures of other degradable polymers of interest. 
 
Originally used as flame retardant materials, polyphosphoesters, also called 
polyphosphates, have emerged as potential drug delivery vehicles over the past 
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two decades.174,193-196 While these polymers are being investigated for delivery of 
a number of different therapeutics, most research has focused on the delivery of 
cancer and gene therapies due to the nucleic acid backbone mimicry of the 
polymer. Hydrophobic polyphosphoesters have been used to deliver taxol in a 
manner significantly better than polyester or soluble taxol alone.196 Hydrophilic 
polyphosphoesters show tremendous promise in the non-viral delivery of 
DNA.197,198 Direct gene delivery by phosphoesters is promising since these new 
polymers are biocompatible and degradable unlike traditional cationic 
polymers.199 
 Another phosphate-based degradable polymer, polyphosphazene, has 
been studied for over 20 years and was originally adapted for use in drug 
delivery by Drs. Cato Laurencin and Robert Langer in 1987.200 
Polyphosphazenes are unique in that they have near universal flexibility for side-
group substitution. Unlike other polymerization processes, the backbone is nearly 
impossible to disrupt by active groups in the side chains and side group 
substitution is performed after polymerization has been completed.201 Provided 
the correct side groups are chosen, the phosphonitrogen bond is hydrolytically 
unstable. These polymers could be used for the delivery of diuretics202, 
vaccines203-205, analgesics,206,207 insulin,208 chemotherapeutics209 and DNA.210 
 While polyamides have been used as suture fibers (nylon)211 and as 
membranes to resist microfloral and enzymatic damage for some time212,213, only 
recently has the research focused on drug delivery applications.214-220 The 
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applications of these polymers range from delivery across the blood-brain 
barrier,214 delivery of DNA,219 and intracellular endolysosomal disruption.216 
Unfortunately, the amide bond is even more hydrolytically stable than the ester 
bond and is 10 fold more stable than an anhydride bond.88 Amides can be 
catalyzed by strong acids or some enzymes, but the enzymes identified so far 
are all bacterial in origin.221 Limited hydrolysis and unknown enzymatic 
degradation have kept polyamides from being further investigated as drug 
delivery vehicles. 
 Polycarbonates were originally developed for biomedical use by Drs. 
Joachim Kohn and Robert Langer in 1986.222 While poly(iminocarbonates) 
initially showed great promise as vaccine adjuvants and delivery vehicles222, the 
carbonate bond was easier to synthesize for their novel tyrosine-derived 
polymers.223 Polycarbonate research has shown that they are resistant to acid 
degradation224, have backbone-independent release over long periods of time223 
and do not result in a high pH microenvironment.225 They have been used to 
deliver analgesics226 and chemotherapeutics.227 While early research is 
promising, being unable to tailor polymer properties to generate desired release 
profiles limits the potential for these materials. 
 In addition to the degradable polymers reviewed above, other novel 
chemistries are being developed. One of the current trends has been the 
development of combination polymers.  Examples of these are poly(ester 
amides), poly(ortho ester amides), poly(anhydride esters) and poly(ether ester 
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amides). These materials are often fabricated in block or alternating structures. 
The thrust behind designing these new polymers is to take advantage of the best 
material properties of each family. 
 
2.3.3 Polymeric Adjuvants 
 
 Degradable polymers have been studied specifically as adjuvants and 
vaccine delivery vehicles for about 15 years.54 Some promising results continue 
to make these attractive materials for the development of single dose 
vaccines.228,229 The ability to stabilize and sustain release of immunogens over 
an extended period of time has been a hallmark of polymeric vaccine delivery 
systems. In addition, other adjuvants (e.g. MPLA and CpG DNA) may be 
encapsulated within polymer particles to synergistically enhance the immune 
response and create pathogen mimicking particles.230 Polymer chemistry has 
been shown to induce immunomodulatory behavior in the host which could 
greatly expand the capabilities of these devices.231 Maintenance of vaccine 
efficacy by polymer-based systems was independent of delivery route (oral, 
intranasal and parenteral), which is another benefit of these materials.232 
 Controlled release of antigen is provided by one of two profiles, pulsatile 
or continuous. Pulsatile release is characterized by short burst of payload 
release, whereas continuous release is achieved when payload is released 
slowly and constantly over time. When APCs take up releasing particles, antigen 
can be delivered intracellularly to facilitate the initiation of the immune response. 
Uptake would seem to be helpful for continuous systems, but disadvantageous 
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for pulsatile delivery. For pulsatile systems, the particles should be a depot that 
can hold off secondary release until a later time. Continuous release has the 
advantage of being able to continually prime the immune response where as 
pulsatile release could cause the induction of high antibody levels mimicking 
traditional multi-dose vaccination schedules. 
 The two most widely studied polymer classes for vaccine delivery are 
polyesters43,53,54,96,97,102,232-236 and polyanhydrides.141,237-247 Other polymers have 
also been evaluated and some have shown success119,137,203-205,222,248-252. Since 
drug delivery by nanoparticles is a newly emerging area of research, most 
published work is on microparticles. 
 
2.3.3.1 In vivo Efficacy 
 
 Polyester microparticles have been the most widely studied polymer 
delivery vehicles. They have been proven effective as vaccine strategies by the 
induction of protective immunity in vivo.54,232-236 Antigen-loaded microparticles 
have been shown to create a depot for antigen delivery and enhanced particle 
uptake by APCs.234 Specifically, PLGA uptake by both macrophages after 
intraperitoneal injection and dendritic cells after intradermal route has been 
published.253 Gupta et al. have shown that blank PLGA microparticles can 
enhance cytokines and cause cell proliferation when they are exposed to either 
macrophages or DCs in vitro.44 Furthermore, PLGA microparticles have been 
shown to enhance antigen presentation via MHC I leading to increased cytotoxic 
T cell activation.254-256 In these studies, many experiments were conducted in 
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vitro and included MPLA or multiple doses. Hence, the results convolute the 
argument of the polymer microparticles by itself. PLGA microparticle-based 
vaccines have been successful in inducing immune response to antigens for 
Yersinia pestis, HIV, Bordatella pertussis, measles virus, diphtheria toxin, ricin 
toxoid, and others.44,257,258 Vaccine delivery routes include intradermal, 
intravaginal, intranasal, oral and parenteral. Vaccinated animals in some studies 
showed responses over a year after single immunization.44,258 Many groups have 
published work on single-dose vaccines based on PLGA microparticles.259-262 
There is no consensus opinion on whether all of this evidence proves PLGA-
based vaccines are more efficacious than alum. Some studies show higher 
antibody titers255 whereas other studies show similar or lower titers.259 In addition 
to titer data, there seems to be incongruent literature about what type of immune 
response PLGA microparticles elicit. These uncertainties may be as attributable 
to antigenic dose, encapsulation method, immunization route and particle 
size.256,263 An example of these effects was demonstrated when intraperitoneal 
delivery induced a Th1 response while intramuscular delivery induced a Th2 
response.256 Despite all of their promise, no PLGA-based vaccines have been 
FDA approved. 
 Polyanhydrides offer many unique advantages over polyesters including 
surface erosion, protein stabilization, and chemistry-dependent degradation. 
They have been approved by the FDA for use as biomedical devices and have 
been shown to be able to be processed into payload-encapsulated 
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microparticles126 and nanoparticles152,264 with relative ease. Kipper et al. were 
able to show unique tetanus toxoid (TT) immunization potential with 
polyanhydride microparticles.231 Microparticles were loaded with small quantities 
of TT and delivered to mice. These experiments showed that antigenicity was 
maintained and that the microparticles acted as superb adjuvants to the toxoid 
vaccine. The most interesting finding was that the particles induced 
immunomodulatory behavior in vivo. Antibody titers (IgG1 & IgG2a) were 
compared by enzyme-linked immunosorbent assay (ELISA) to determine the 
balance of the (Th2 – antibody-mediated v Th1 – cell-mediated) response 
generated by the vaccine. As expected, TT alone gave a Th2 dominant 
response. When TT was delivered solubly as well as encapsulated within 20:80 
CPH:SA or 50:50 CPH:SA microparticles, a balanced Th1/Th2 response was 
initiated. This is the first time polyanhydride-based immunomodulatory behavior 
has been shown in vaccination. Recent research has shown that 50:50 
CPTEG:CPH nanoparticles delivered in a single-dose intransally were able to 
induce long-lived, high affinity IgG1 antibody that was able to maintain long-term 
protection against plague through 23 weeks post-vaccination.265 With strong 
immune responses generated by polyanhydrides of different size and chemistry 
with different vaccine candidates, polyanhydrides can be utilized as a vaccine 
delivery platform against a wide array of infectious diseases. 
 There have been limited efforts focused on polyanhydride-based vaccine 
delivery. Some groups have looked at the use of vaccine delivery with conjugate 
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chemistry systems that contain an anhydride bond and a secondary degradable 
bond. One attempt was the design of poly(anhydride-co-imide) with the adjuvant 
L-tyrosine (trimellitylimido-L-tyrosine) copolymerized with CPH:SA.239,243 While 
vaccine release from these polymers was shown to be carried out in a controlled 
manner and polymer implants inserted into mice were well tolerated, publications 
about this material ceased 10 years ago. More recent literature by Pfeiffer et al. 
shows the design of poly(ester-anhydride):poly(β-amino ester) microparticles and 
nanoparticles to deliver DNA to macrophages.244 While the work does not 
explicitly state that the novel material will be used for DNA vaccines, other 
research conducted by this group gives evidence that this is probably the 
intended use. 
 Few studies have been conducted to compare polyesters to 
polyanhydrides as vaccine delivery vehicles, but some give insight into the 
potential of polyanhydrides.  Mathiowitz et al. showed that microparticles and 
nanoparticles composed of poly(fumaric-co-sebace acid) (FA:SA) had strong 
adhesive interactions with gastrointestinal mucosal surfaces in rats.266 PLA 
showed minimal association and uptake.  Facilitating mucosal adhesion is crucial 
to delivering antigen for mucosal immunization. Unsurprisingly, they showed that 
DNA and anticoagulant delivery by FA:SA was much better than that from PLA 
alone. In a different study, methylvinylether / maleic anhydride polymer 
[p(PVM/MA)] nanoparticles were shown to effectively deliver Salmonella 
enteridities extract yielded a 80% survival among mice. While p(PVM/MA) is non-
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degradable, it still possesses an anhydride group. In another study, these 
particles were able to provided non-specific protection against S. enteridis 
whereas poly(ε-caprolactone) could not. Thus, the anhydride chemistry was able 
to mediate an interaction the polyester could not. 
 Two other polymers (chitosan and polyphosphazenes) have also shown 
significant promise as degradable vaccine delivery vehicles. Chitosan, a 
synthetic cationic polysaccharide, has been shown to be easy to formulate into 
antigen-loaded microparticles.267 The immune bias for chitosan microparticle 
vaccines seems to be more dependent on the route of delivery than the nature of 
the adjuvant itself.268,269 Intranasal delivery of N-trimethyl chitosan chloride (TMC) 
loaded with diphtheria toxoid enhanced the immune response over a 
conventional alum-based vaccine.267 This was probably a result of nasal mucosa 
penetration by chitosan due to its mucoadhesive properties.270,271 Additional 
studies have shown that molecular weight and quaternization of the trimethyl 
group greatly influence the magnitude of the immune response.272 
  Polyphosphazenes have also shown promise as an adjuvant. In 1997, 
Payne et al. of the Virus Research Institute showed 
poly[di(carboxylatophenoxy)phosphazene] (PCPP) was a very potent adjuvant 
for influenza.204 In this experiment they used soluble polymer, so it functioned 
only as an adjuvant and not as a delivery vehicle as well. The adjuvanticity was 
so robust that after a single immunization, mice maintained high antibody titers 
for at least 6 months. It would take 3 separate doses of adjuvants like MP59 and 
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MPLA to reach the antibody titers found in this study. The group showed that 
even aged mice (22 months old) could achieve a robust antibody response to 
influenza virus adjuvanted with PCPP. In addition, they were able to show its 
adjuvanticity potential with other immunogens for the diseases hepatitis B and 
herpes. In 2007, Muwiri et al. published work recently studying PCPP as well as 
a new polymer, poly[di(sodium carboxylatoethylphenoxy)phosphazene] 
(PCEP).205  Chemical structures of these two polymers are shown in Fig. 2.12. 
 
 
Figure 2.12. Chemical structures of PCPP and PCEP polymers. 
 
Their work demonstrates that both polyphosphazines are excellent adjuvants for 
BSA and X:31 H3:N2 influenza antigen. BSA-specific antibody titers were greatly 
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increased for both adjuvants and X:31-specific antibody titers were very high for 
just PCEP when compared to both the antigen alone and the antigen with alum. 
In addition, the number of IFN- cytokine secreting cells were much greater for 
X:31 with PCEP than with any of the other groups. This complements the higher 
IgG2a titers seen compared to any of the other groups. All mice had high 
numbers of IL-4 cytokine secreting cells. This data shows the potential to use 
soluble phosphazene polymers as adjuvants over traditionally accepted ones. 
 
2.3.3.2 Polymer Interactions with APCs 
 
 While degradable polymers have been shown to function as strong 
adjuvants in vivo, little is known about the mechanisms these materials exploit to 
initiate a robust immune response. Recent research has studied the interaction of 
polymers with APCs to better understand this behavior. Cell population-based 
analysis has been used to investigate the overall effect of particles on a group of 
cells. In research with APCs, this includes utilizing flow cytometric evaluation of 
fluorescently-tagged monoclonal antibody detection of cell surface marker 
expression and enzyme-linked immunsorbent assay or multiplex conjugated-
bead assay detection of APC secreted cytokines. These techniques have been 
used to probe the interactions between APCs and particles composed of 
polyesters229,273-277 and polyanhydrides.279-283 
 Research conducted by Audran et al. was the first to show PLGA 
microparticles could enhance antigen delivery to APCs, dendritic cells (DCs) and 
macrophages, in vitro.229 Further studies conducted by Samuel and 
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colleagues273,274 showed that PLGA nanoparticles were able to be internalized by 
dendritic cells (DCs) and enhance cell surface marker expression (MHC II and 
CD86). When particles were loaded with MUC1 mucin peptide, a cancer antigen, 
DCs were able to activate naïve T cells and cause their proliferation. Most recent 
work by Babensee and colleagues275-277 verified the results observed by Samuel 
but also showed that PLGA particles were able to induce production of the pro-
inflammatory cytokines TNF-α and IL-6. Sharp et al. showed that PLGA particles 
may be causing DC activation by specific uptake through the NALP3 
inflammasome causing the production of the strong pro-inflammatory cytokine, 
IL-1β.278 While a very interesting mechanistic finding, this result was only seen 
when DCs were co-stimulated with PLGA particles and LPS. 
 Research conducted by Narasimhan and colleagues has shown a direct 
correlation between polyanhydride chemistry and DC activation.279-283 Petersen 
et al. showed that as nanoparticle hydrophobicity increased, DC cell surface 
marker expression (MHC II, CD40, CD86 and CD209) decreased, but cytokine 
secretion (IL-6 and IL-12p40) increased.279,280 This result was supported by 
Torres et al. for polyanhydride microparticles.281 Ulery et al. have shown that 
nanoparticles composed of a copolymer of very hydrophobic and amphiphilic 
monomers can induce both enhanced DC cell surface marker expression and 
cytokine secretion.282 Carrillo et al. further enhanced DC activation by chemically 
modifying the nanoparticle surface with carbohydrates that facilitate uptake 
through pathogen recognition receptors.283 
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 Another technique, individual cell-based analysis, has been used to probe 
how particles traffic within cells. Fluorescent microscopy of individual cells 
probed with fluorescently-tagged monoclonal antibodies detecting intracellular 
processes is used to determine particle internalization and intracellular fate. This 
technique has been utilized to probe trafficking of degradable polymer particles in 
many cell types284-286, but only recently has been used to investigate particle 
behavior in APCs.264,281,287 Shen et al. shows that antigen loaded PLGA 
nanoparticles are able to escape the endosomal pathway and deliver payload to 
the cytosol for extended periods of time.287 PLGA stimulated DCs were able to 
induce antigen-specific T cell IL-2 production at a 1000-fold lower antigen dose 
than soluble antigen alone showing promise for DC mediated immune activation 
with these particles. Ulery et al. has shown polyanhydride chemistry dictates 
intracellular nanoparticle behavior in both macrophages264 and DCs.281 It was 
shown that hydrophobic nanoparticles get internalized, trafficked by the 
endosomal pathway and degraded over 48 hours. In contrast, nanoparticles 
composed of a copolymer of hydrophobic and amphiphilic monomers were 
actually able to mediate their own aggregation inside lysosomal compartments. 
This behavior is very similar to bacterial replication giving these particles a 
“pathogen-like” effect that may explain their ability to enhance cell surface marker 
expression and cytokine secretion unlike any other chemistry. Coupling of these 
two types of analyses (population and individual cell) may lead to further 
understanding of how degradable polymers initiate immune responses. 
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2.4 Yersinia Pestis 
 
2.4.1 Introduction & History 
 
 Yersinia pestis, the causative agent of plague, is a gram-negative, non-
motile bacterium which has caused three pandemics, a number of endemics and 
is believed to have killed between 50 to 200 million people.288 The first plague, 
the Justinian plague, began in Egypt in 541 A.D. and quickly spread throughout 
Mediterranean Europe and the Middle East over the next 3 years. For the next 
100 years, epidemics cycled every 8 to 12 years causing untold damage that 
eventually spread to the entire known world.289 After a 700 year lapse of nearly 
any disease outbreak, the Black Death (2nd Plague Pandemic) wreaked havoc, 
especially on Europe from 1347 to 1351 A.D. During that time an estimated 30 to 
40% of Europe’s population perished (17 to 28 million people).290 While 
epidemics quelled after the 1480’s, outbreaks were still prevalent until the 17th 
century. The most recent event, the third pandemic, is believed to have started in 
the 1850’s in China following war in the Yunnan Province.291 By 1900, plague 
had spread throughout the world including the United States. Endemics 
continued to occur into the 1950’s, but the spread of disease and its mortality 
were lowered due to better public health measures and antibiotics, respectively. 
It was during the Hong Kong epidemic of 1894 that Alexandre Yersin and 
Shibasaburo Kitasato independently announced the identification of the cause of 
the pandemic, Yersinia pestis.292 Yersin was able to use antiserum developed 
from the isolated organism to cure a plague patient in 1896.293 During the 
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Manchurian outbreak, L-T. Wu was able to identify the difference between the 
bubonic and pneumonic form of the disease. This led to the use of aerosol 
protective measures that significantly decreased transmission. Also, this 
outbreak led to L-T. Wu, R.P. Strong, and others recording the most detailed 
epidemiological and pathological human data on pneumonic plague we have 
today.294,295 Since this last outbreak, significant research has been conducted to 
define post-exposure antibiotic protocols and to design Y. pestis vaccines. While 
antibiotics can prevent mortality and allow for the host to clear infection, they 
must be administered within 24 hours of exposure or their effectiveness is 
severely diminished.292 Often antibiotics (e.g., ciprofloxacin) are administered to 
anyone who may have been exposed to prevent the onset of disease. In order to 
better fight this disease, development of new therapeutic and prophylactic 
strategies is necessary. 
 
2.4.2 Bacterial Function within Host 
 
 In order to develop new strategies, the transmission route of Y. pestis 
needs to be understood. Hosts tend to be one of three types, mammal, flea, or 
human. 
 
2.4.2.1 Mammals 
 
 The natural reservoirs of Y. pestis are rodents and other animals, whereas 
humans are only accidental hosts. Since plague can infect such a wide variety of 
mammals, response is host-specific. Many carnivores from domestic dogs and 
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ferrets to coyotes and skunks are highly resistant to plague. Ingestion of plague 
infected rodents usually leads to limited to mild disease that is normally survived 
and cleared.296 On the other hand, domestic cats and some rodents appear to be 
responsive to plague.297 Like most infections the response by a population is very 
heterogeneous. While many cats and rodents die, some will have moderate 
natural resistance due to weakened bacteria or previous exposure. The 
persistence of bacteria within these hosts makes them a reservoir of bacteria that 
can be transmitted among the population and externally to other species. 
Particularly good enzoonotic hosts include some rats and gerbils298 and in the 
United States, mice and voles.299 Transfer occurs between rodents through 
contact and to other species by fleas. 
 
2.4.2.2 Flea 
 
 The flea is the most common transfer vehicle of plague from animal to 
animal and animal to human. Two days after fleas uptake bacteria from an 
infected host through a blood meal, bacteria replicate and create cohesive brown 
masses that extend through the stomach, the proventriculus, helps break up 
blood for digestion, and the esophagus. Between 3 and 9 days the clotting coats 
the entire proventriculus making it nearly impossible for the flea to gain 
sustenance.300 The flea attempts to digest blood, but instead the blood mixes 
with the bacteria and gets delivered back into the host. The flea is unable to feed 
and eventually dies, but not without first delivering Y. pestis to a new host. 
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2.4.2.3 Human 
 
 In humans, there are two common mechanisms for bacterial uptake. The 
first is that a flea regurgitates infected blood during an attempted feed. This 
route, when bacteria is originally contracted from a rodent, is called sylvatic 
plague.298 It is by far the most common method by which humans contract 
plague. The number of human plague cases by this method greatly increases 
when rodent populations go through widespread epizootics.301 It is theorized that 
this occurs because fleas typically get their meals from rodents, but are forced to 
change species during epizootic incidences. Often they change over to feeding 
on humans and deliver Y. pestis. The other route is by person to person transfer 
often in the form of respirator droplets. 
 When Y. pestis enters the human host, it is able to cause any of three 
types of clinical disease: bubonic, systemic or pneumonic. If bacteria are 
delivered by flea transfer, then bubonic plague is the most likely disease to 
progress. Bacteria travel to the lymph node where they take up residence 
between 2 and 6 days after initial exposure. The lag time for this response is 
thought to be caused by the bacteria adjusting from the flea in which temperature 
was ambient-dependent to a host with a much higher body temperature. Patients 
usually experience fever, headaches, the chills and the development of very 
tender lymph nodes (buboes). Symptoms can also include nausea and 
vomiting.302 These buboes become necrotic with rapidly growing populations of 
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bacteria. Finally, bacteremia or secondary septicemia ends up causing death in 
about 50% of patients who get bubonic plague. 
 In primary septicemic plague, the bubo is not formed and sepsis occurs 
within just a few days. Mortality rate is about 50% or greater because 
undifferentiated sepsis treatment is not effective against Y. pestis. The disease 
looks clinically similar to septeciemias caused by other gram-negative bacteria. 
Onset of primary septicemia is very quick (1 to 2 days) and can be deadly. 
 A rare third disease can occur which is called primary pneumonic plague. 
In this case, bacteria are able to move to the lung and take up residence. In one 
study, about 12% of patients developed pneumonic plague from bubonic or 
septicemic plague.303 Rapid onset of flu-like symptoms occurs with a persistent 
cough followed by the production of very bloody sputum. The incubation period 
for pneumonic plague is only 1 to 3 days. This form of the disease is nearly 100% 
deadly and allows for the aerosol transfer of bacteria infected droplets from 
person to person. Once transferred from lungs to lung, death occurs even more 
rapidly since the bacteria have adjusted to the human lungs as sites of 
proliferation and response. Most cases of pneumonic plague over the last 80 
years304 have been determined to be transmitted as aerosols by house cats and 
not by human to human transmission.303  
 In any disease type, it has been shown that Y. pestis is able to accumulate 
with limited interaction with neutrophils and apoptosis of macrophages.305 The 
inability for the host to facilitate a robust immune response and the speed with 
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which plague become virulent indicates the need for research into efficacious 
vaccine systems. 
 
2.4.3 Quorum Sensing in Y. Pestis 
 
 Quorum sensing (QS) is the use of population density dependent chemical 
switches to regulate gene activation and deactivation. It was first described in 
Vibrio fischeri where if the concentration of cells is high enough the bacteria 
activate the production of a fluorescent protein.306 A cartoon depicting V. fischeri 
and its QS system is shown in Fig. 2.13. 
 
Figure 2.13. LuxIR network for V. fischeri. LuxI produces a QS agent synthase. 
This synthase produces small molecular weight signals that can freely diffuse in 
and out of cells. When the concentration of cells is not very high (left) there is not 
very much free signal. In comparison, if the concentration of cells is high (right) 
then a significant amount of signal permeates the cells.  When this happens, 
LuxR binds the signal and becomes an active promoter for the luciferase operon.  
Upon activation luciferase is produced in high quantities and the cell fluoresces. 
It is worth noting that promotion of the luciferase operon also produces more LuxI 
causing a positive feedback loop. Reprinted and modified from Ref. 306. 
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While V. fischeri uses QS for bioluminescence there are many bacteria that 
exploit this technique to allow for density dependent virulence. Staphylococcu 
aureus, Staphylococcus pseuodintermedisum, Salmonella typhimurium and 
Pseudomonas aeruginosa all utilize QS systems to regulate their virulence.307 Y. 
pestis utilizes three QS systems with two being of the LuxIR subtype (Fig. 2.20) 
and the other being LuxS (AI-2 peptide) together for biofilm formation and 
potentially for virulence applications.308-311 While the complete function of these 
QS systems has yet to be elucidated, their use in biofilm formation provides 
evidence that the bacteria are using them to promote their survival in the host. By 
identification of proteins that are up- or down-regulated during QS, new vaccine 
candidates could be identified and explored for their ability to induce protection. 
 
2.4.4 Bioterrorism Potential 
 
 While the need for therapy and prophylaxis for naturally occurring Y. 
pestis infections is important, it is the bacteria’s potential as a bioterrorism agent 
that has truly driven the research towards improved pre- and post-exposure 
treatments. The ability for plague, especially in the pneumonic form, to 
disseminate quickly, kill within a matter of days, and be released in large 
population centers makes Y. pestis one the greatest bioterrorism threats faced. 
For this reason, the United States Department of Defense and Centers for 
Disease Control and Prevention have categorized plague as a Category A 
pathogen.312 The ability for plague to be genetically altered to overcome 
vaccination is an additional fear. The F1 antigen is considered a potent 
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immunogen that vaccinates hosts against the capsular protein of Y. pestis.313 
Sadly, the same tools that allowed for the isolation of good subunit vaccines like 
F1 can be used to engineer weapons-grade bacteria that can overcome these 
vaccines. In 1995, Drozdov et al. showed that a simple mutagenesis could 
remove the capsule of Y. pestis and maintain virulence.314 Additional mutations 
like this could prove disastrous for defense against this bioterror agent. Another 
issue is the development of antibiotic resistant strains of plague. Luckily, the 
limited exposure of humans to Y. pestis since the inception of antibiotics has kept 
nearly all naturally occurring infections very susceptible to traditional antibiotic 
treatment protocols. In 1996, two cases of significantly antibiotic resistant strains 
in Madagascar caused a major scare. The potentially more dangerous aspect is 
that due to the high sequence homology of the Y. pestis resistance plasmid to 
one found in Typhi, many experts wondered if this new strain was created by 
natural or synthetic means.315 Also, it has become known since the collapse of 
the Soviet Union that they were actively trying to weaponize plague.316 In order to 
combat the issue of bioterrorism, robust and efficacious vaccination strategies 
must be developed.  
  
2.4.5 Vaccines against Y. Pestis 
 
 The first plague vaccine developed consisted of a heat-killed broth of 
densely grown, virulent Y. pestis.317 This formulation probably conveyed great 
immunity to bubonic plague, but it was known to cause serious adverse side-
effects including a fever of 102 °F. Further testing showed that this early vaccine 
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was not protective of mice to the pneumonic form of plague.318 A formalin-killed 
vaccine was developed by Meyer and colleagues in the mid 1950’s319 and was 
used by the United States military during the Vietnam War, but has since been 
withdrawn when it was shown to have no protection against pneumonic 
plague.320 Since these early vaccines, the development of subunit vaccines has 
been the main focus for the field. The two most commonly research recombinant 
proteins are caf1 (F1) and LcrV (V).321 Most recently a fusion protein (rF1-V) of 
the two has been evaluated as a plague antigen.322,323 While original mouse 
studies looked very promising, rF1-V failed to convey protection to African green 
monkeys even though protection was shown in cynomolgus macaques.324 The 
absence of a plague vaccine in the United States has made this research field all 
the more important to protect American citizens and military personnel against 
bioterror attacks. 
 
2.5 Conclusions 
 
 While a number of different degradable polymers could be used in vaccine 
delivery, polyanhydrides exhibit properties like surface erosion, chemical 
flexibility, and protein stabilization that make them excellent candidates as 
adjuvants. The advancement in laboratory techniques now enables the 
fabrication and delivery of nanoparticles. Nanoparticles may be used as mucosal 
vaccine delivery systems due to their favorable characteristics of size and 
surface charge. Novel delivery systems have become more important as vaccine 
research has transitioned from the use of whole killed and live attenuated to 
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subunit vaccines. The reduction in side effects and allergy has been coupled with 
decrease immune response. Polyanhydride particle-based systems that can 
function both as adjuvants and slow-release delivery devices show great 
promise. Once these materials are designed, they can be evaluated with known 
or novel immunogens for their ability to convey protection against a number of 
different diseases including those with bioterrorism implications. 
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CHAPTER 3 
 
Research Objectives 
 
The overall goal of this research is to design single-dose vaccines utilizing 
antigen-encapsulated polyanhydride nanoparticles that function as both excellent 
adjuvants and robust vaccine delivery vehicles. In order to achieve this goal, 
development of a nanoparticle fabrication technique was undertaken. Once this 
was accomplished, nanoparticles of varied polymer chemistry were evaluated in 
vitro and ex vivo for their ability to interact and stimulate antigen presenting cells. 
The knowledge gained from these experiments was used to rationally choose 
which polymer chemistries held the greatest potential as single-dose vaccine 
delivery vehicles. The polyanhydride nanoparticles with favorable characteristics 
were loaded with Yersinia Pestis antigens and evaluated in vivo in murine 
models for their capacity to induce a protective immune response. 
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The specific goals (SG) for this research are as follows: 
 
SG1: Development of a technique to reproducibly fabricate polyanhydride 
nanoparticles. 
SG2: Assessment of the effect of polymer chemistry on in vitro interactions 
between antigen presenting cells and polyanhydride nanoparticles. 
SG3: In vivo evaluation of polyanhydride nanoparticles as single-dose vaccine 
delivery vehicles for the vaccine immunogen F1-V against Y. pestis. 
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4.1 Abstract 
 
 Polyanhydride nanoparticles hold significant promise for use as vaccine 
delivery vehicles. In order to better understand the mechanism by which these 
materials initiate an immune response they were incubated with THP-1 human 
monocytic cells. Nanoparticles were prepared by an anti-solvent 
nanoprecipitation technique yielding particles with similar morphology and 
particle diameter (200 to 600 nm) regardless of polymer chemistry. Exposure of 
nanoparticles composed of poly(sebacic acid) (poly(SA)) and 20:80 poly(1,6-
bis(p-carboxyphenoxy)hexane-co-sebacic acid) (CPH:SA) to THP-1 monocytes 
were readily internalized whereas 50:50 CPH:SA nanoparticles had more limited 
uptake. When soluble fluorescently-labeled protein antigen was added with 
nanoparticles, antigen uptake was enhanced and negatively correlated to the 
hydrophobicity of the polymer chemistry. These results demonstrate the 
importance of choosing polyanhydride chemistries that facilitate enhanced 
interactions with antigen presenting cells in order to initiate and efficacious 
immune response. 
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4.2 Introduction 
 
Bioerodible polymers have been studied as sustainable drug delivery 
vehicles for over thirty years.1 Polyesters and polyanhydrides are two families of 
polymers that are strong candidates for biomedical applications because of the 
biocompatibility and bioresorbability of their degradation products.2 While 
polyesters, like poly(lactic-co-glycolic acid) (PLGA), have been approved by the 
FDA for many in vivo applications3, their suitability for use as vaccine delivery 
vehicles is affected by various factors that negatively impact the stability of 
encapsulated proteins. Research has shown that the bulk-erodible polyester-
based delivery systems display rapid release profiles4,5, produce low pH 
microenvironments6-8, and can initiate moisture-induced protein aggregation.8-10 
In contrast, polyanhydrides are characterized by chemistry-dependent surface 
erosion and payload release11-13, moderate pH microenvironments8,14,15, and 
superior protein stabilization capabilities.10,16,17 Polyanhydrides have been used 
to deliver plasmid DNA18, proteins9,13,17, small molecular weight drugs11,19,20, and 
vaccine immunogens.21,22 Alterations of polyanhydride chemistry modulate 
degradation rates from weeks to years, which can be exploited to best fit 
therapeutic needs.9,11,16 In addition, polyanhydride microspheres used as vaccine 
delivery vehicles exhibit a chemistry-dependent, immunomodulatory adjuvant 
effect.22 Kipper et al. showed that encapsulating tetanus toxoid (TT) into 
polyanhydride microspheres or co-delivering free TT along with the microspheres 
enhanced antigen-specific immune responses.22 Furthermore, the relative 
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increase of polymer hydrophobicity effectively modulated the immune response 
from a dominant TH2 (humoral) to a TH0 (balanced) response. Together, these 
results indicate that polyanhydride microspheres are promising vehicles for 
vaccine delivery. 
The polyanhydride chemistries used in the present study were copolymers 
of sebacic anhydride (SA) and 1,6-bis-(p-carboxyphenoxy)hexane (CPH) 
anhydride with chemical structures as shown in Fig. 4.1. With aromatic rings, the 
CPH unit is more hydrophobic than the aliphatic SA unit. Copolymers containing 
higher compositions of CPH have been shown to degrade slower than 
copolymers containing higher compositions of SA.9 
 
Figure 4.1.  Chemical structure of a random CPH:SA copolymer. 
 
In the last several decades, the in vivo applications utilizing polymer 
carriers have transitioned from the use of large, implanted pellets (~1 mm) to 
microspheres (~5-20 µm) and, more recently, to nanoparticles (~100-500 nm).1,11 
In comparison to implants, microspheres (or nanoparticles) do not require 
surgical insertion or removal22, can carry multiple drugs20,23, and are 
phagocytosed by antigen presenting cells (APCs).24 Inhalation and intranasal 
delivery can be realized with particles that are small enough to pass through the 
finely porous networks of the nasal, tracheal, and pulmonary filtration 
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systems.25,26 In addition, multiple studies have shown that polymeric 
nanoparticles gain ready access into sub-mucosal layers of the nasal-associated 
and gut-associated lymphoid tissues much more effectively than 
microparticles.27-29 In comparison to microspheres, nanoparticles were more 
readily taken up by APCs.30 Collectively, these characteristics underpin the 
functional diversity and enhanced capabilities of polyanhydride nanoparticles. 
In order for polyanhydride nanoparticles to function as efficacious vaccine 
adjuvants, they must possess the ability to stimulate and to deliver antigen to 
APCs. In the present study, we chose to use confocal microscopy to monitor both 
intracellular and extracellular interactions between polyanhydride nanoparticles 
and APCs.31 In addition, confocal microscopy allowed us to monitor the potential 
for polyanhydride nanoparticles to deliver antigen via the endocytic pathway by 
evaluating the co-localization of polyanhydride nanoparticles within specific sub-
cellular compartments associated with antigen processing and presentation. Our 
data demonstrate that systematically varying the chemistry of polyanhydride 
nanoparticles (by varying the SA content in a CPH:SA copolymer) significantly 
affects nanoparticle uptake by human monocytic cells. In addition, we 
demonstrate that polymer chemistry significantly influences the uptake of a 
model antigen (Eα tagged with red fluorescent protein (RFP), henceforth referred 
to as Eα-RFP) by human monocytic cells. 
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4.3 Materials and Methods 
4.3.1 Materials 
Sebacic acid (99%), 4-hydroxybenzoic acid, 1-methyl-2-pyrrolidinone 
anhydrous (99.5%), 1,6-dibromohexane (98.5%) and fluorescein-isothiocyanate-
dextran (FITC-dextran) were purchased from Sigma-Aldrich (Milwaukee, WI). All 
other chemicals were purchased from Fisher Scientific (Pittsburgh, PA) and used 
as received. 
 
4.3.2 Polyanhydride Synthesis and Characterization 
Synthesis of SA and CPH pre-polymers and copolymers was performed 
as previously described.11,12,32 The resulting polymers were characterized using 
1H nuclear magnetic resonance to verify polymer chemistry, gel permeation 
chromatography to analyze molecular weight, and differential scanning 
calorimetry to determine glass transition temperature and crystallinity. All 
properties evaluated showed that the synthesized polymers were within accepted 
ranges.11,12 
 
4.3.3 Nanoparticle Fabrication and Characterization 
FITC-dextran loaded nanoparticles were fabricated by polyanhydride anti-
solvent nanoencapsulation (PAN), similar to the method reported by Mathiowitz 
et al. for poly (fumaric acid-co-sebacic acid) polymers.33 Polymer (145.5 mg) was 
dissolved in methylene chloride (5 mL) held at room temperature for poly(SA) 
and 20:80 CPH:SA and 0 °C for 50:50 CPH:SA. FITC-de xtran (4.5 mg) was 
105 
 
homogenized at 30,000 rpm for 30 s to create a suspension. The 
polymer/fluorescein solution was rapidly poured into a bath of petroleum ether at 
an anti-solvent to solvent ratio of 80:1 held at room temperature for poly(SA) and 
20:80 CPH:SA and -40 °C for 50:50 CPH:SA (due to th e lower glass transition 
temperature for 50:50 CPH:SA12). Polymer solubility changes due to the 
presence of anti-solvent caused spontaneous particle formation. These particles 
were removed from the anti-solvent by filtration (by aspiration using a Buechner 
funnel and Whatman #2 filter paper) and then dried overnight under vacuum. The 
procedure yielded a fine powder with at least 70% recovery. The nanoparticle 
morphology was investigated using scanning electron microscopy (JEOL 840A, 
JEOL Ltd., Tokyo, Japan). Particle diameter was determined using quasi-elastic 
light scattering (Zetasizer Nano, Malvern Instruments Ltd., Worcester, United 
Kingdom). 
 
4.3.4 Culture of THP-1 Human Monocytes and Co-Incubation with 
Nanoparticles 
Tissue culture and subsequent derivation of adherent THP-1 monocytes 
was performed according to published reports34 with some modification.35 Briefly, 
suspension THP-1 cells were grown using RPMI 1640 growth medium 
supplemented with 10% newborn calf serum, 10 mM Glutamax, 25 mM HEPES, 
and 10 µg/ml penicillin-streptomycin antibiotics (complete RPMI). Adherent 
monocytes were derived from suspension cultures by stimulating cells with 5 nM 
phorbol-12-myristic-13-acetate (PMA) in 24 well tissue culture plates containing 
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10 mm glass coverslips inside each well at a final density of 5 x 105 cells per well. 
Following 24 h PMA incubation, cultures were washed with PBS and incubated in 
fresh RPMI without PMA for 24 h before nanoparticles were added. 
Polyanhydride nanoparticles (in the form of dry powder) of poly(SA), 20:80 
CPH:SA, or 50:50 CPH:SA were weighed and added to PBS (pH 7.4) at a stock 
concentration of 10 mg/ml. The nanoparticles were briefly sonicated on ice for a 
total process time of 1 min alternating 10 sec pulse ON, 15 sec Pulse OFF. 
Nanoparticles (100 µg) were added to cell culture medium (0.5 ml/well), briefly 
mixed by pipetting before cultures were returned to the incubator (37 °C, 5 % 
CO2). In order to evaluate phagocytic processes, the nanoparticles were co-
incubated with the THP-1 cells for 30 min. Cultures were washed and the cells 
were placed back in the incubator for 2 h prior to analysis. In order to evaluate 
endocytic processes, the nanoparticles were co-incubated with the THP-1 cells 
for 6 h. Cultures were washed and the cells were placed back in the incubator for 
48 h prior to analysis.  
 
4.3.5 Fluorescence Microscopy Techniques 
To observe time-dependent interactions of individual monocytes with 
nanoparticles, cell monolayers incubated with nanoparticles at indicated times 
were fixed with 4% para-formaldehyde (PFA) for 10 min at room temperature, 
and then washed with PBS. Acidic vesicles and lipid rafts in cell monolayers were 
labeled by incubating cells for 20 minutes prior to fixation with either Lysotracker 
at 1/2000 dilution (DND-99) (acidic vesicles) or Alexa555 conjugated Cholera 
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Toxin β-subunit (CTx) at 1/150 dilution (lipid rafts) (Molecular Probes-Invitrogen, 
Carlsbad, CA). Intracellular structures were immunofluorescently stained by 
incubating fixed coverslips with primary and secondary antibodies in PBS 
containing albumin and 0.1% saponin (BSP).35 Stained coverslips were washed 
and mounted on glass slides (Pro-Long w/ Dapi; Molecular Probes-Invitrogen). 
Epifluorescence and immunofluorescence microscopy was performed using 
either an Olympus IX-61 inverted microscope equipped with blue, green, and red 
filter sets with a cooled CCD camera or by an inverted Leica NTS laser scanning 
confocal microscopy (LSCM). The LSCM is equipped with ApoChromatic 63X oil 
and 100X oil objectives and UV, Argon, Krypton and HeNe laser lines equipped 
with three photomultiplier detection tubes. Optimal step size for Z-stack image 
data was determined empirically from pilot studies to be 0.3 µm (data not shown). 
Co-localization analysis, relative nanoparticle uptake comparisons, and final 
images were prepared using Image J v1.36b image analysis software loaded 
with particle counting algorithms.36 
 
4.3.6 Eα–RFP Antigen Preparation and Cellular Internalization by 
Monocytes  
The IPTG inducible Eα–RFP expression construct was a kind gift from Dr. 
Marc Jenkins (Department of Microbiology, Center for Immunology, University of 
Minnesota Medical School)37 and introduced into Escherichia coli DH5α by heat 
shock followed by selecting 50 mg/ml ampicillin-resistant colonies. Broth cultures 
of transformed bacteria were induced by the addition of IPTG to overnight 
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cultures. Crude cell lysates prepared using the Novagen Bugbuster extraction 
reagent (Gibbstown, NJ) were passed through a Profinity IMAC Ni-charged resin 
(BioRad; Hercules, CA). Imidazole eluted E–RFP protein was dialyzed 
overnight at 4⁰C and final preparations were shown to be free of detectable LPS 
contamination by the limulus ameobocyte lysate (LAL) assay (Cambrex; 
Walkersville,MD). Fluorescence signal intensity of internalized protein was 
detected using standard epi-fluorescence microscopy employing 
TRITC/rhodamine filter set with 510-560 nm excitation and 575-645 emission. 
Image black levels for the RFP protein were set using cells not incubated with 
RFP. Exposure times for RFP detection were kept constant throughout the 
experimental groups to facilitate accurate comparative analysis. Bar graphs of 
the relative pixel intensity of internalized RFP were calculated from RAW-RFP 
images using the ImageJ/plugin/histogram function. These bar graphs reveal the 
relative pixel intensity of the RFP protein detected in the presence and absence 
of nanoparticles. 
 
4.4 Results and Discussion  
4.4.1 Nanoparticle Characterization 
Scanning electron photomicrographs of the FITC-dextran loaded 
nanoparticles of varying formulations are presented in Fig. 4.2. The 
photomicrographs show that the nanoparticles appear circular, and while there 
are some small variations, the nanoparticles appear to be relatively uniform in 
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size and shape. Light scattering size distribution data show nanoparticle 
diameters for all polymers fall between 200 and 800 nm. 
 
Figure 4.2.  Scanning electron photomicrographs of (a) poly(SA) nanoparticles, 
(b) 20:80 CPH:SA nanoparticles and (c) 50:50 CPH:SA nanoparticles. 
 
Every batch of nanoparticles was analyzed by light scattering and particle 
size was measured using duplicate samples. For each chemistry, the data from 
three different lots of nanoparticles were analyzed in this manner and the 
compiled data are shown in Table 4.1. The standard deviations were determined 
for the overall accumulated size distribution data for each polymer. 
 
Table 4.1. Particle size data compiled from light scattering measurements (n=3). 
Data reported as mean + S.D. 
 
 
 
Analysis shows that there is no statistically significant difference in average 
particle size among the different polymer formulations (p = 0.13). This data 
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demonstrates that polyanhydride nanoparticles fabricated by the PAN method 
can be reproducibly prepared with similar morphology and particle diameters 
regardless of copolymer chemistry. Having particles of similar size is important in 
limiting the variables that are introduced into in vitro and in vivo experiments, 
especially when evaluating a chemistry effect. While not statistically significant, 
there was a slight trend for a positive correlation between particle size and CPH 
content. The thermodynamic and kinetic balance between nucleation and growth 
dictates the resulting average particle size. The soluble material must nucleate 
particles and then more material can either precipitate on the surface of these 
already formed particles or new particles can be nucleated.38 Copolymers with a 
higher SA content are less hydrophobic and more non-polar than those with a 
higher CPH content. When precipitating from a polar solvent into an aliphatic 
anti-solvent bath, copolymers with a higher SA content may more easily nucleate 
new particles. If nucleation is favored, it would cause more particles to be formed 
with a smaller average particle size. 
 
4.4.2 Cellular Interactions of Nanoparticles with Human Monocytes 
To determine whether or not polymer chemistry affects nanoparticle 
internalization and intracellular deposition within APCs, adherent human THP-1 
monocytes were incubated separately with poly(SA), 20:80 CPH:SA, or 50:50 
CPH:SA nanoparticles. LSCM was utilized to evaluate and compare the 
interactions of nanoparticles with cells and their eventual intracellular localization.  
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4.4.2.1 Internalization 
Nanoparticles introduced into cell culture medium did not form large 
aggregates and remained uniformly dispersed prior to settling at the bottom of 
the tissue culture well during co-incubation with the THP-1 cells. The 
nanoparticles were then rapidly internalized by THP-1 monocytes via cellular 
events consistent with phagocytosis (Fig. 4.3). Observations supporting this 
conclusion include: centrifugation-independent internalization, temperature-
dependent internalization, and internalization in the absence of an 
overabundance of extracellular particles. Confocal photomicrographs in Fig. 4.3 
depict monocytes that have internalized nanoparticles and values presented in 
Table II indicate the percentage of THP-1 cells per field of view that have cell 
associated nanoparticles at 2 or 48 h post internalization. Cells were imaged at 
1000x total magnification and the average number of cells in each Field of View 
(FOV) was 25. FOVs were randomly selected and the numbers of THP-1 cells 
with FITC-loaded polyanhydride nanoparticles or without nanoparticles were 
recorded. The percentages and standard deviations of THP-1 cells positive for 
nanoparticles were calculated from values for ≥ 5 FOV images for each 
nanoparticle chemistry and time point (cells with FITC-nanoparticles/total # cells 
scored). The total cells scored positively for clear association with FITC 
nanoparticles were combined from data collected over 3 to 5 independent 
experiments. 
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Figure 4.3.  Confocal photomicrographs of FITC-labeled polyanhydride 
nanoparticles internalized by THP-1 cells. Adherent monocytes were incubated 
with nanoparticles for 30 min before cultures were washed and continued to 
incubate for an additional 2 h. Poly(SA) and 20:80 CPH:SA nanoparticles were 
internalized to a much greater extent than 50:50 CPH:SA nanoparticles. The 
majority of internalized poly(SA) and 20:80 CPH:SA were bound by cholesterol 
rich membranes as indicated by the high degree of co-localization (yellow). 
Representative images were captured by LSCM. Lipid rafts (red) were identified 
using Alexa 555 CTx (Molecular Probes). Scale bar = 5 µm. 
 
The data in Table II indicate that in the experiments designed to evaluate 
phagocytosis where the exposure to nanoparticles was 30 min, the least 
hydrophobic polymers (i.e., poly(SA)) were more rapidly internalized than the 
more hydrophobic (i.e., CPH-containing) polymers (Fig. 4.3). In contrast, the 48 h 
50:50 CPH:SA 
20:80 CPH:SA 
poly(SA) 
Lipid Rafts 
+ 
Nanoparticles 
Co-localized 
Pixels 
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co-localization experiments employ a longer exposure time of nanoparticles with 
cells lasting 6 h. In these experiments, where endocytosis plus the initial 
phagocytosis would contribute to total nanoparticle uptake, it was observed that 
~96% of the THP-1 cells contained poly(SA) nanoparticles, while the uptake of 
20:80 CPH:SA and 50:50 CPH:SA was ~91% and ~53%, respectively. These 
results indicate that the chemistry of the polyanhydride nanoparticles affects the 
uptake efficiency of these nanoparticles by monocytes. Unlike CPH-containing 
nanoparticles, poly(SA) nanoparticles were more efficiently internalized by 
phagocytic processes (30 min exposure to cells) and did not require the 
extended time (6 h) associated with endocytic processes. The more hydrophobic 
nanoparticles (i.e., CPH-rich) were not internalized by phagocytic pathways 
(~8%). However, with time, all the formulations were internalized; but, 50:50 
CPH:SA nanoparticles were internalized to a lesser extent (~53%, Table 4.2). 
Overall, monocyte uptake of polyanhydride nanoparticles correlated with 
decreasing hydrophobicity (poly(SA) > 20:80 CPH:SA > 50:50 CPH:SA). 
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Table 4.2. Association of polyanhydride nanoparticles with THP-1 cells varies 
depending on polymer chemistry. 
 
 Percent monocytes with internalized nanoparticles* 
Polymer 2 h (phagocytosis) 48 h (phagocytosis and 
endocytosis) 
Poly(SA) 87.9% ± 17.1% 96.3% ± 11.7% 
20:80 CPH:SA 27.1% ± 14.8% 91.2% ± 22.2% 
50:50 CPH:SA 8.1% ± 10.6% 53.1% ± 28.3 
* Average percent nanoparticles positive monocytes calculated per 100x field of        
view image 
 
The degree of hydrophobicity may indeed be an important factor 
influencing nanoparticle uptake. The hydrophobic nature of these particles may 
facilitate their interaction with hydrophobic lipid-rich micro-domains in the cell 
membrane, including lipid rafts. Lipid rafts contain many membrane-bound 
cofactors that comprise receptor complexes, such as receptors for complement, 
antibodies, and serum and extracellular matrix proteins.39-41 In contrast with 
phagocytosis, increasing polymer hydrophobicity may facilitate closer 
nanoparticle-to-cell interactions and increase the probability of internalization 
through constitutive endocytic or macropinocytotic pathways. These hydrophobic 
interactions facilitate nanoparticle internalization by direct association with 
surface receptors or through direct interactions with the plasma membrane. 
Pattern recognition receptors (PRRs) are another key receptor type found in lipid 
rafts of APCs. PRRs recognize pathogen-associated molecular patterns 
(PAMPs), which are repetitive patterns of molecular structure found in both 
microorganisms and the mammalian host. Examples of PAMPs include 
lipopolysaccharide and flagellin from bacteria as well as hyaluronan and uric acid 
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from mammals. All of these PAMPs signal “danger” to the host, be it in the 
context of infection or cellular damage. Hydrophobic characteristics have been 
ascribed to many PAMPs and are thought to be partly responsible for their 
immunostimulatory properties.42 In the context of the polyanhydride co-polymers, 
surface patterns of intervening hydrophobic moieties (e.g., CPH and SA, Fig. 1) 
may mimic PAMPs, facilitate interactions with PRRs present on the surface of 
APCs and subsequently enhance the ability of APCs to activate T cells.43,44 
Internalization and co-localization of antigen-loaded nanoparticles within the 
endocytic pathway may, in part, explain the adjuvanticity of polyanhydride 
nanoparticles.22 
 
4.4.2.2 Intracellular localization 
In general, intracellular degradation and processing of exogenously 
presented antigen occurs when lysosomes fuse with late endosomes containing 
antigen. In contrast, endogenous antigen is processed within the cytosol by the 
proteosome.45 As a result, antigen fate (i.e., MHC I vs MHC II presentation) is 
largely decided by intracellular location. Given the variable surface chemistry 
presented by the different polyanhydrides, we compared the intracellular 
distribution of nanoparticles 48 h after uptake. The majority of particles were 
found to be intact and located within membrane bound vesicles that were 
characterized as acidic and CTx+ (Fig. 4.4). In these photomicrographs, the 
FITC-dextran containing nanoparticles appear green, the acidic vesicles are red 
(Lysotracker), and co-localized nanoparticles within acidic vesicles appear 
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yellow. The data indicates that all the polyanhydride chemistries studied resulted 
in localization of the nanoparticles into the acidic phagolysosomal compartments 
of the cells. 
The majority of these particles were rapidly targeted to the endosomal 
pathway, and localized within vesicles exhibiting staining characteristics and 
morphology consistent with MHC class II loading compartments.46 Interestingly, 
at 48 h, ~10 % of the poly(SA) and 20:80 CPH:SA nanoparticles did not appear 
to be located within acidic or lipid raft containing vesicles (Fig. 4.4). A lack of 
localization within either of these major intracellular compartments is consistent 
with nanoparticles that are free within the cellular cytosol. Release of antigen 
from nanoparticles located within the cellular cytosol would be processed and 
directed to the MHC class I presentation pathway.45 However, the data presented 
in Fig. 4.3 and Fig. 4.4 would only suggest that small amounts of nanoparticles 
can reach the cytosol and that further experiments are warranted.  
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Figure 4.4.  Confocal images of the intracellular localization of FITC-
nanoparticles in THP-1 cells 48 h after uptake. Representative images were 
captured by LSCM and processed using ImageJ. The majority of internalized 
poly(SA) and 20:80 CPH:SA nanoparticles were bound by cholesterol rich 
membranes as indicated by the high degree of co-localization (yellow). Acidic 
vesicles (two left columns) were identified using the pH responsive Lysotracker 
dye (red) and cholesterol rich lipid rafts (two right columns) were visualized using 
Alexa 555 conjugated CTx (red, Molecular Probes). Note the general absence of 
FITC 50:50 CPH:SA nanoparticles compared to 20:80 CPH:SA and poly(SA). 
Scale bar = 5 µm. 
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4.4.2.3 Antigen Internalization 
As previously discussed, polyanhydride nanoparticles serve as antigen 
delivery platforms to APCs. Nanoparticle-encapsulated immunogens would be 
released intracellularly following internalization and slow polymer degradation.8 
However, some nanoparticles may release antigen prior to uptake, providing a 
source of soluble antigen delivered to APCs via endocytosis. To evaluate the 
ability of nanoparticles to stimulate soluble antigen internalization by APCs, the 
THP-1 cells were co-incubated with blank nanoparticles (poly(SA), 20:80 
CPH:SA, or 50:50 CPH:SA) and soluble Eα–RFP37, fixed, and visualized by 
epifluorescence microscopy. Representative photomicrographs and bar graphs 
summarizing cell associated RFP data are provided in Fig. 4.5.  
Comparisons among the three chemistries reveal that after 2 h of co-
incubation, all three chemistries dramatically increased the amount of soluble 
antigen internalized by monocytes. A potential mechanism for the increase in 
uptake stimulated by the nanoparticles is that the protein itself is able to adsorb 
on the surface of nanoparticles that are then subsequently internalized by the 
APC. However, preliminary experiments failed to detect soluble RFP adsorbing 
onto FITC-labeled nanoparticles (data not shown) and culture conditions include 
ample amounts of serum proteins present in the 10% fetal bovine serum 
supplemented medium. Moreover, the dramatic increase in the uptake of soluble 
RFP was also detected for 50:50 CPH:SA even though these particles serve as 
poor targets for uptake themselves (Table 4.2, Fig. 4.3, and Fig. 4.4). This data 
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demonstrates that the chemistry of the polyanhydride nanoparticles influences 
the ability of APCs to internalize soluble antigen.
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Figure 4.5.  Enhanced uptake of soluble Eα-RFP (red) antigen by monocytes 
(nuclei blue) after co-incubation with polyanhydride nanoparticles for 2 h. Data 
demonstrated that the poly(SA) nanoparticles enhanced antigen internalization 
more readily than did 20:80 CPH:SA followed by 50:50 CPH:SA. Representative 
epifluorescent images were captured and processed using identical exposure 
and ImageJ settings. Adjacent bar graphs summarize the average amount of 
RFP detected per cell. Pixel areas within each image correspond to relative 
intensity of RFP signal detected inside cells. Values from 3 randomly selected 
fields of view were used to calculate averages and standard deviation. Scale bar 
= 5 µm. 
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4.5 Conclusions 
 
The unique cellular interactions elicited by polyanhydride nanoparticles 
are a function of the particles’ distinct physical and chemical properties that 
modulate the persistence and intracellular distribution of antigen. We observed 
that polyanhydride nanoparticles were internalized and distributed within human 
monocytes in a chemistry-dependent manner. We also found that chemistry 
influences the ability of nanoparticles to enhance monocytic uptake of soluble 
antigen. Together, this data highlights the importance of chemistry in designing 
polyanhydride nanoparticles as vaccine or drug delivery vehicles intended for 
specific applications and/or targeting desired intracellular locations. 
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5.1 Abstract 
 
Polyanhyrides, a class of hydrolytically degradable polymers, possess 
monomer chemistry flexibility allowing for their material properties and 
degradation to be tailored for use in biomedical applications in controlled payload 
release, tissue engineering and/or immune response activation. In the design of 
polyanhydride nanoparticle-based vaccine adjuvants and delivery vehicles, 
understanding the mechanism by which these materials initiate an immune 
response is critical. This study investigates the effect nanoparticle polymer 
chemistry has on the activation of murine bone marrow derived dendritic cells 
(DCs). To assess activation, cell surface marker expression, cytokine secretion 
and intracellular nanoparticle trafficking, were studied. Nanoparticle 
hydrophobicity determined DC response yielding cellular activation, shock or 
even death. These results suggest that polymer chemistry can be chosen to best 
tailor nanoparticles to initiate desired immune responses. 
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5.2 Introduction 
 
 Recent advancements in vaccine development have focused on the 
utilization of adjuvants (non-specific immune boosting substances) to increase 
effectiveness. Everything from viral1,2 and bacterial vectors3,4 to liposomes5,6 and 
degradable polymers7-10 have been investigated to design systems that function 
not only as adjuvants, but also as directed delivery vehicles. Research on 
degradable polymers holds significant promise since material properties can be 
tailored to allow for long-term8,10 and directed antigen delivery7,8, immune 
activation9,10, and immune response modulation.10 
 While a number of degradable polymer families (polyesters7,9, 
polyethers11,12, and polyphosphazenes13,14) have been investigated for vaccine 
applications, polyanhydrides offer a unique set of features making them 
exceptional candidates. Polyanhydrides are FDA-approved, biocompatible, 
bioresorbable, surface-eroding polymers in which polymer degradation and 
subsequent payload release are directly correlated to polymer chemistry.15-18 
Copolymers based upon the combination of the monomers 1,6-bis-(p-
carboxyphenoxy) hexane (CPH) and sebacic acid (SA) and copolymers based 
upon 1,8-bis-(p-carboxyphenoxy-3,6-dioxaoctane) (CPTEG) and CPH were 
studied in this work. Research has shown that these polyanhydride chemistries 
possess moderate pH microenvironments (upon degradation)19,20, protein 
stabilization capabilities10,15,16,21-23, and immune activation potential.10,22,24,25 In 
order to utilize polyanhydrides as vaccine delivery vehicles, particle formation 
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offers the ability to protect encapsulated antigen from rapid immune clearance 
and mediate antigen delivery to cells of interest. Recent research has shown that 
antigen-loaded polyanhydride nanoparticles (<1 µm) delivered as a single-dose, 
intranasal formulation conveyed protection against lethal challenge with Yersinia 
pestis, the causative agent of plague, through 23 weeks post-vaccination.26 While 
nanoparticles were able to convey long–term immunity, the underlying 
mechanism(s) for this action are still unclear. 
 The cells primarily responsible for the initiation of an immune response are 
a class of antigen presenting cells (APCs) called dendritic cells (DCs).27 Once 
DCs are activated they increase their cell surface expression of major 
histocompatibility complexes (MHC) I and II to present processed antigen to T 
cells in lymphoid organs.  Also, they express co-stimulatory molecules (CD40, 
CD80, and CD86) that assist in directing T cell activation.27 Other markers, like 
CD209, are thought to play a role in T cell activation as well as assist in DC 
trafficking to the draining lymphoid tissue.28 Activated DCs also secrete chemical 
signals called cytokines (IL-1β, IL-6, IL-10, IL-12, TNF-α, etc.) to help direct the 
nature of the immune response.27 By better understanding the mechanism by 
which polymer particle adjuvants induce DC activation in vitro, rational design of 
vaccines can be accomplished before experiments are conducted in animal 
models and clinical trials in humans. 
When evaluating interactions of polymer particles with cells, two types of 
analyses have been commonly utilized: cell population-based and individual cell-
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based. In cell population-based analysis, the overall effect of particles on a group 
of cells is explored. In research with DCs, this includes utilizing flow cytometric 
evaluation of fluorescently-tagged monoclonal antibody detection of cell surface 
marker expression and enzyme-linked immunsorbent assay or multiplex 
conjugated-bead assay detection of DC secreted cytokines. These techniques 
have been used to probe the interactions between DCs and particles composed 
of polyesters29-33, polyethers34, polyethylenimides35,36, chitosan37,38, and 
polyanhydrides.22,25 These studies have shown that polymer particles of certain 
chemistries have the capacity to activate DCs. In individual cell-based analysis, 
fluorescent microscopy of individual cells probed with fluorescently-tagged 
monoclonal antibodies detecting intracellular processes is used to determine 
particle internalization and intracellular fate. This technique has been utilized to 
probe trafficking of degradable polymer particles in lung cancer cells39, cervical 
cancer cells40, kidney cells41, epithelial cells42,43, and dendritic cells.44 These 
studies have provided insights on how cells internalize and process degradable 
particles via the endocytic pathway. 
Each type of analysis generates data that describes the effect of particles 
on cells, but only provides one side of the argument. While cell population-based 
analysis has shown the capacity for particles to initiate immune responses, the 
mechanisms that govern these reactions have yet to be detailed. In contrast, 
individual cell-based analysis has been used to follow intracellular particle 
trafficking, but these observations have yet to be linked to their effect on cells. 
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The primary focus of this study was to correlate intracellular polyanhydride 
nanoparticle behavior observed by fluorescent microscopy to DC activation as 
evaluated by cell surface marker expression and cytokine secretion. Linking 
these experiments will fulfill a critical gap in our understanding of how particles 
interact with immune cells at both the cellular and molecular levels, thereby 
enabling new insights on nanoparticle-based vaccine design. 
 
5.3 Materials and Methods 
 
5.3.1 Materials 
 
 Carboxylic diacid monomer synthesis required the use of 1,6-
dibromohexane (98.5%), 4-hydroxybenzoic acid (96%), 1-methyl-2-pyrrolidinone 
anhydrous (99.5%), triethylene glycol (99%) purchased from Sigma Aldrich (St. 
Louis, MO); 4-p-fluorobenzonitrile (98%) purchased from Apollo Scientific 
(Stockport, Cheshire, England); and sodium hydroxide, sulfuric acid, acetonitrile, 
dimethyl formamide, toluene and potassium carbonate purchased from Fisher 
Scientific (Fairlawn, NJ). Polymerization and nanoparticle fabrication utilized 
acetic anhydride, chloroform, petroleum ether, ethyl ether, methylene chloride 
and hexanes from Fisher Scientific. DC culture medium included RPMI 1640, 
HEPES buffer, L-glutamate, penicillin-streptomycin, gentamycin acquired from 
Mediatech (Herndon, VA); heat inactivated fetal calf serum acquired from Valley 
Biomedical (Winchester, VA); and granulocyte macrophage colony stimulating 
factor (GM-CSF) acquired from PeproTech (Rocky Hill, NJ). Materials used in 
flow cytometry were: mouse serum; unlabeled CD36/16 FcɣR purchased from 
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Southern Biotech (Birmingham, AL); β-mercaptoethanol and unlabeled rat 
immunoglobulin (rat IgG) purchased from Sigma Aldrich; peridinin-chlorophyll 
proteins-Cy5.5 (PerCP/Cy5.5) conjugated anti-mouse MHC II (I-A/I-E) (clone 
M5/114.15.2) purchased from Biolegend (San Diego, CA); unlabeled hamster 
IgG, phycoerythin (PE) conjugated anti-mouse MHC I (clone 34-1-2s), 
fluorescein isothiocyanate (FITC) conjugated anti-mouse CD86 (clone GL-1), 
allophycocyanin (APC) conjugated anti-mouse CD40 (clone 1C10), Alexa Fluor® 
700 anti-mouse CD11c (clone N418), biotin conjugated anti-mouse CIRE (DC-
SIGN or CD209) (clone 5H10), and allophycocyanin-Cy7 (APC-Cy7) conjugated 
streptavidin; and corresponding isotypes: PerCP-Cy5.5 conjugated rat IgG2b κ 
(clone RTK 4530), PE conjugated rat IgG2 K (clone eBM2a), FITC conjugated rat 
IgG1 K (clone eBR2a), APC conjugated rat IgG2a K (clone eBR2a), Alexa Fluor 
700 conjugated Armenian hamster IgG (clone eBio299Arm), and biotin 
conjugated rat IgG2a (clone eBM2a). All of these reagents were purchased from 
e-Bioscience (San Diego, CA). E. coli lipopolysaccharide (LPS) was acquired 
from Sigma Aldrich. FluoSpheres® (0.2 µm and 2 µm), FITC-loaded carboxylate-
modified polystyrene particles (PS particles), were purchased from Invitrogen 
(Carlsbad, CA). 
 
5.3.2 Polymer Synthesis, Nanoparticle Fabrication, and Characterization 
 
 Synthesis of CPTEG and CPH diacids, SA and CPH pre-polymers, and 
CPH:SA and CPTEG:CPH copolymers was performed as previously 
described.17,18,45 The resulting polymers were characterized using 1H nuclear 
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magnetic resonance spectroscopy to verify polymer chemistry and purity, gel 
permeation chromatography to analyze polymer molecular weight, and 
differential scanning calorimetry to determine polymer glass transition 
temperature and crystallinity. All properties evaluated showed that the 
synthesized polymers were within accepted ranges.17,18,45 
 Both FITC-dextran loaded and blank nanoparticles were fabricated by the 
polyanhydride anti-solvent nanoencapsulation (PAN) method modified from the 
protocol reported in Ulery et al.24 Polymer was dissolved in methylene chloride at 
0 °C at a concentration of 25 mg/mL. For loaded nan oparticles, FITC-dextran 
was sonicated for 15 s at a concentration of 1% of total batch weight to form a 
suspension. The polymer/polysaccharide solution was rapidly poured into a bath 
of pentane held at -20 °C at an anti-solvent to sol vent ratio of 80:1. Penetration of 
anti-solvent into the polymer solution microenvironment caused spontaneous 
nanoparticle formation; the particles were subsequently filtered by Whatman No. 
50 paper filters in a Buchner funnel. This procedure yielded a fine powder with at 
least 60% recovery. Nanoparticle morphology was investigated using scanning 
electron microscopy (SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan). Quasi-elastic 
light scattering (QELS) was employed using a Zetasizer Nano (Malvern 
Instruments Ltd., Worchester, UK) to determine nanoparticle size. 
 
5.3.3 Culture and Stimulation of C57BL/6 DCs 
 
 DCs were harvested and grown as described previously.25 C57BL/6 mice 
were euthanized, cell were extracted from bones and plated at approximately 5 
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million cells per T75 flask in GM-CSF DC media. They were fed on days 3 and 6 
and plated into 24 well plates on day 8 at a density of approximately 2 million 
cells per well in 1 mL GM-CSF free DC media. Wells were split into those 
analyzed for nanoparticle-induced cell surface marker expression and cytokine 
secretion and those analyzed for intracellular trafficking of nanoparticles. 
Stimulation groups for cell surface marker expression and cytokine 
secretion consisted of: 400 ng/mL LPS (positive control); no stimulation (NS) 
(negative control); and 250 µg/mL of blank nanoparticles composed of poly(SA), 
50:50 CPH:SA, poly(CPH), 50:50 CPTEG:CPH, and poly(CPTEG). Treatments 
were applied to the DCs on day 9 and incubated for 48 h. On day 11, 
supernatants were collected for cytokine analysis and cells were stained for flow 
cytometry analysis. 
 Stimulation groups for intracellular trafficking of nanoparticles consisted of: 
polystyrene particles (PS particles), which were used as a control for particle 
internalization and 250 ug/mL of 1% FITC-dextran loaded nanoparticles 
composed of poly(SA), 50:50 CPH:SA, poly(CPH), 50:50 CPTEG:CPH, and 
poly(CPTEG). Treatment were applied to the DCs on day 9 and allowed to 
incubate for 30 min or 6 h. Cultures were washed with PBS and replenished with 
media to incubate for an additional 2 h or 42 h, respectively. Cells were then 
stained for intracellular trafficking markers as described below. 
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5.3.4 Cell Surface Markers 
 
 Expression of cell surface markers including MHC I, MHC II, CD40, CD86, 
CD209 and CD11c was assessed after 48 h incubation as described 
previously.25 Adherent DCs were placed on ice and harvested by vigorous 
pipetting, then placed in polystyrene tubes (BD Falcon™, Franklin Lakes, NJ) 
and centrifuged at 4 °C at 250 rcf for 10 min. Cell s were blocked with Fc blocking 
solution (PBS buffer with 0.1% anti-CD16/CD32, 0.1% unlabeled hamster IgG, 
1% rat IgG, 1% mouse serum, 0.1% sodium azide, and 1% FBS) for 1 h. After 
blocking, the DCs were stained by monoclonal antibodies for the cell surface 
markers above and fixed with a stabilizing fixative (BD Bioscience, San Jose, 
CA). The samples were analyzed using a Becton-Dickinson FA 
CSCanto flow cytometer (San Jose, CA) and FlowJo (TreeStar Inc, Ashland, 
OR). Cells were gated for single-cell populations and cell viability before cell 
surface marker expression analysis was conducted. 
 
5.3.5 Cytokine Production 
 
 After incubation of the DCs with the stimulation treatments for 48 h, 200 
µL of supernatants were collected from the cultures and assayed for the 
presence of IL-6, IL-10, IL-12p40, and TNF-α using the Luminex® Multiplex assay 
system (Austin, TX). 
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5.3.6 Intracellular Trafficking 
 
 To observe time-dependent intracellular trafficking of individual 
nanoparticles within DCs, cells were assessed similarly to previous work.24 DCs 
were incubated for the indicated times, fixed with 4% paraformaldehyde (PFA) for 
10 min at room temperature, and then washed with PBS. Polymerized actin was 
labeled by incubating DCs for 10 min after fixation with Alexa 568 conjugated 
phalloidin mushroom toxin (Molecular Probes-Invitrogen) at a 1:150 dilution. 
Lysosomes were immunofluorescently stained by incubating fixed coverslips with 
ID-4B anti-LAMP-1 (lysosomal-associated membrane protein 1) monoclonal 
antibody at a 1:50 dilution followed by Cy3-conjugated goat anti-mouse at a 
1:150 dilution in PBS containing albumin and 0.1% saponin (BSP). Stained 
coverslips were washed with PBS and mounted on glass slides (Pro-Long w/ 
Dapi; Molecular Probes-Invitrogen). Epifluorescence and immunofluorescence 
microscopy were performed using either an using either an Olympus IX-71 
inverted microscope with blue, green, and red filter sets with a cooled CCD 
camera or by an inverted Olympus FluoviewTM 1000 laser scanning confocal 
microscopy (LSCM). The LSCM is equipped with ApoChromatic x63 oil and x100 
oil objectives and UV, Argon, Krypton and HeNe laser lines equipped with three 
photomultiplier detection tubes. Z-stack step size of 0.25 µm was used. 
Intracellular trafficking analysis and final images were prepared using ImageJ 
v1.36b (NIH, Bethesda, MD) image analysis software loaded with particle 
counting algorithms.46 
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5.4 Results 
 
5.4.1 Nanoparticle Characterization 
 
 Scanning electron photomicrographs of nanoparticles of varying chemistry 
are shown in Fig. 5.1a-e. The photomicrographs show that the nanoparticles 
appear spherical and relatively uniform in size and shape. Light scattering size 
distribution analysis (Fig. 5.1f) confirms that the diameters for nanoparticles of all 
chemistries fall between 100 nm and 1 µm. Every batch of nanoparticles was 
analyzed in duplicate with a total of three distinct batches for each of the 
chemistries being evaluated. Mean particle diameters and corresponding 
standard errors are shown in the caption to Fig. 5.1. No statistically significant 
differences were found in the size and morphology of blank versus 1% FITC-
dextran loaded nanoparticles (data not shown). Particle size followed a trend of 
smaller particles corresponding to increased oxygen content in the polymer 
backbone (i.e., higher CPTEG or CPH content). This observation may be 
explained by the nucleation and growth theory of precipitation47, wherein the 
increased oxygen content may make the polymer less soluble in the non-solvent 
(pentane) forcing increased nucleation sites leading to smaller particle size. 
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 (a)  (b)  (c) 
 
 
 
 
 
 (d)  (e) 
 (f) 
 
Figure 5.1. Representative SEM images of nanoparticles composed of (a) 
poly(SA), (b) 50:50 CPH:SA, (c), poly(CPH), (d) 50:50 CPTEG:CPH and (e) 
poly(CPTEG) with scale bars of 500 nm. (f) An overlap of particle size as 
determined by QELS averaged from three independent samples.  Average 
particle diameters and standard errors are as follows: poly(SA) (616 ± 62), 50:50 
CPH:SA (415 ± 44), poly(CPH) (310 ± 36), 50:50 CPH:SA (206 ± 27) and 
poly(CPTEG) (170 ± 17). 
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5.4.2 Cell Population-Based Analysis 
 
 Nanoparticles of varying chemistries and controls (negative: NS and 
positive: LPS) were co-incubated with bone-marrow derived DCs for 48 h and 
cell surface markers of interest (MHC I, MHC II, CD40, CD86, CD209, and 
CD11c) were stained by fluorescently tagged monoclonal antibodies and 
evaluated by flow cytometry. Side-scatter v forward-scatter plots (Fig. 5.2) show 
that increased nanoparticle hydrophobicity correlated to an overall population of 
less viable cells (shift of cells to a low forward-scatter profile). 
 
 
 
 
 
Figure 5.2. Side-Scatter (SSC-A) versus Forward-Scatter (FSC-A) plots for each 
treatment group.  All graphs are representative images. 
 
Analysis showed that only <3% of cells co-incubated with poly(CPH) 
nanoparticles (which was the most hydrophobic chemistry studied) were viable 
(data not shown), so further flow cytometry analysis was not conducted with this 
chemistry. Cells incubated with all other chemistries had cell population viability 
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>60% and this population was composed of >83% CD11c (DC specific marker) 
positive cells (data not shown). Supplemental Fig. 5.3 shows peak shifts for the 
markers of interest from isotype (non-specific binding) controls. 
 
 
 
Figure 5.3. Cell surface marker expression (mean fluorescence intensity (MFI)) 
as represented with histograms of MHC I, MHC II, CD40, CD86 and CD209 after 
48 h incubation of polyanhydride nanoparticles with DCs. All histograms are 
representative images and show the peak shift between the treatment group 
(light grey) from the isotype control (dark gray). 
 
Mean fluorescence intensities (MFIs) for each marker for each stimulus were 
averaged and the data is complied in Fig. 5.4. Surface expression of MHC I, 
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MHC II, CD40, and CD86 was enhanced for cells incubated with LPS or 
nanoparticles composed of poly(SA) or 50:50 CPTEG:CPH over the non-
stimulated cells. Expression remained at background levels for cells stimulated 
with 50:50 CPH:SA or poly(CPTEG) nanoparticles. CD209 expression was 
dramatically increased due to the presence of poly(SA), 50:50 CPTEG:CPH, or 
poly(CPTEG) nanoparticles and remained near background in the presence of 
LPS or 50:50 CPH:SA nanoparticles. CD209 expression increased for cells 
exposed to less hydrophobic nanoparticles. 
 
 
 
Figure 5.4. Analysis of MHC I, MHC II, CD40, CD86 and CD209 expression by 
C57BL/6 DCs. These histograms represent the complete set of results of MFI 
expression of cell surface markers for cells stimulated with NS, LPS and 
nanoparticles composed of poly(SA), 50:50 CPH:SA nanoparticles, 50:50 
CPTEG:CPH, and poly(CPTEG). Data is representative of a minimum of 8 
replicates per group. Error bars represent standard error. Average MFIs for NS 
(negative control) stimulated DCs are MHC I (799), MHC II (1069), CD40 (702), 
CD86 (503) and CD209 (702). # = p-value < 0.005 and * = p-value < 0.001 
(compared to NS). 
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 Supernatants from these cell cultures were analyzed by a multiplex bead 
assay (LUMINEX®) for the presence of IL-6, IL-10, IL-12p40 and TNF-α. For all 
nanoparticle chemistries, no IL-10 production above background levels was 
detected (data not shown). Statistically significant quantities of IL-6, IL-12p40 and 
TNF-α were secreted from cells exposed to 50:50 CPH:SA or 50:50 CPTEG:CPH 
nanoparticles, but not cells exposed to poly(SA) or poly(CPTEG) nanoparticles 
(Fig. 5.5). The cytokine release caused by nanoparticles was considerably less 
than LPS induced levels as shown in the figure caption. This result follows the 
trend that more hydrophobic particles elicited increased cytokine levels. 
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 (a) 
 (b) 
 (c) 
 
Figure 5.5. Analysis of (a) IL-6, (b) IL-12p40, and (c) TNF-α secretion by 
C57BL/6 DCs.  These histograms represent the complete set of results of 
cytokine secretion by DCs stimulated with NS and nanoparticles composed of 
poly(SA), 50:50 CPH:SA, 50:50 CPTEG:CPH, and poly(CPTEG). Data is 
representative of a minimum of 8 replicates per stimulation group.  Error bars 
represent standard error.  Average cytokine concentrations in pg/ml secreted by 
LPS (positive control) and poly(CPH) stimulated DCs are IL-6 (>50,000 and 
3,800), IL-12p40 (>50,000 and >50,000) and TNF-α (3,700 and 1,900). * = p-
value ≤ 0.002 (compared to NS). 
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5.4.3 Individual Cell-Based Analysis 
 
  Polyanhydride nanoparticles and PS particles (0.2 and 2 µm) were pulsed 
with DCs for 30 min and 6 h, washed and fixed and fluorescently stained at 2.5 h 
and 48 h post-exposure, respectively for polymerized actin and LAMP-1. 
Polymerized actin staining was used to determine nanoparticle internalization by 
DCs and LAMP-1 staining was used to determine the presence of internalized 
nanoparticles in lysosomal vesicles. Confocal microscopy showed nearly all 
nanoparticles co-localized with polymerized actin (data not shown), which is 
utilized to traffic material within the cell. This result indicates that the 
nanoparticles were internalized by DCs. 
 The ability for nanoparticles to be processed by the exogenous pathway 
requires processing through lysosomal vesicle fusion.48 To determine the nature 
of the internalization process, pulse times of 30 min and 6 h were chosen to allow 
for analysis of phagocytic events and a combination of phagocytic and endocytic 
events, respectively. Confocal photomicrographs of LAMP-1 staining at 2.5 h 
post-incubation (Fig. 5.6) showed little difference in overall cell morphology and 
nanoparticle appearance. Because it is difficult to distinguish between individual 
nanoparticles and aggregates of nanoparticles using confocal imaging and 
because polyanhydride nanoparticles are able to undergo deformation-induced 
particle aggregation to form blob-like clusters, the data are presented as 
“nanoparticle agglomerates.” The PS particles control showed significant 
internalization of the smaller 0.2 µm particles, but few larger 2 µm particles. This 
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is an expected result for the 30 min pulse time. Nearly all nanoparticle 
agglomerates regardless of chemistry were shown to be associated with  
LAMP-1 (yellow). 
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Figure 5.6. Confocal photomicrographs of FITC-encapsulated PS particles and 
polyanhydride nanoparticles (green) internalized by BMDC fixed and stained at 
2.5 h. Lysosomes (red) were identified using an anti-LAMP-1 (ID-4B) antibody. 
No major differences in dendritic cell health and morphology were observed 
among the different particles chemistries which are reflected in the representative 
wide field images above. Higher magnification of a selected region of interest 
provides greater detail of the spatial relationship between particles and 
lysosomes. All chemistries were internalized with the majority of particles found 
inside LAMP-1+ vesicles as evidenced by overlap (yellow). Scale bar = 10 µm. 
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In contrast, confocal photomicrographs of LAMP-1 staining at 48 h post-
incubation (Fig. 5.7) showed significant differences in cell health and nanoparticle 
agglomerate morphology based on polymer chemistry. The PS particles control 
showed significant internalization of both small and large particles as anticipated. 
DCs exposed to nanoparticle agglomerates of the most hydrophobic chemistry 
(poly(CPH)) were in far lower concentrations than those incubated with other 
chemistries and the cells exposed to poly(CPH) showed significant rounding 
indicating poor health. DCs exposed to moderately hydrophobic nanoparticle 
agglomerates (50:50 CPH:SA and 50:50 CPTEG:CPH) had larger aggregates 
persisting inside the cell. These aggregates appear to be co-localized with 
LAMP-1 indicating their presence inside lysosomal vesicles. DCs exposed to the 
least hydrophobic nanoparticles (poly(SA) and poly(CPTEG)) show diffusive 
staining correlating to significant release of encapsulated payload. In addition, 
many of the least hydrophobic aggregates appear to be unassociated with 
lysosomes indicating they may have escaped to the cytosol. An interesting 
observation for 50:50 CPTEG:CPH nanoparticle agglomerates is that they 
appear to be both persisting inside lysosomes forming very large aggregates and 
releasing their payload payload  in these vesicles (bright yellow). 
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Figure 5.7. Confocal photomicrographs of FITC-encapsulated PS particles or 
polyanhydride nanoparticles (green) internalized by BMDC fixed and stained at 
48 h. Lysosomes (red) were identified using an anti-LAMP-1 (ID-4B) antibody. 
Significant differences in dendritic cell health and morphology can be seen in 
representative wide field images shown for each of the particle chemistries 
examined. In addition chemistry-dependent agglomerate morphology differences 
were observed. Scale bar = 10 µm. 
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 In order to quantify the population of nanoparticle aggregates found 
intracellularly, epifluorescent microscopy was used to generate images that were 
processed by ImageJ. All analyzed particles were ordered by size and graphs of 
agglomerate area (in µm2) v agglomerate count are shown in Fig. 5.8. The PS 
control had large populations of individual particles corresponding to 0.2 µm at 
2.5 h and 2 µm at 48 h post-incubation as expected. There were very few 
poly(CPH) nanoparticle agglomerates present at either time-point coinciding with 
the few number of cells present. Both 50:50 CPH:SA and 50:50 CPTEG:CPH 
showed similar nanoparticle agglomerate count trends at 2 h, but opposing 
trends at 48 h. There were fewer 50:50 CPH:SA nanoparticle agglomerates at 48 
h compared to at 2 h with only slightly increased size distribution. In contrast, 
50:50 CPTEG:CPH nanoparticle agglomerates had an almost 10-fold increase in 
quantity with an expansive size range. Agglomerates of poly(SA) and 
poly(CPTEG) had very similar trends at both 2 h and 48 h except there were 
more poly(SA) agglomerates at both time-points. The quantitative data strongly 
agrees with the qualitative trends and nanoparticle agglomerate behavior 
observed in Fig. 5.6 and Fig. 5.7. 
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Figure 5.8. Chemistry dependent pattern of agglomerates distribution at both 2.5 
and 48 h. Morphometric data for individual particles were graphed on scatter 
plots to reveal striking differences in particle size distributions and total particle 
counts between 2.5 and 48 hr time points. All agglomerates for each chemistry 
were ordered by size (smallest to largest). Log scales for both axes were used to 
allow for easier comparison among times and chemistries. 
 
5.5 Discussion 
 
 The ability for nanoparticle-based adjuvant and delivery systems to 
modulate the immune response based solely upon their polymer chemistry would 
enhance our understanding of how these adjuvants interact with immune cells 
and lead to rational design of effective nanovaccine platforms. In order to initiate 
an immune response the capacity for adjuvant chemistry to modulate DC 
behavior was studied. Our aim in this study was to combine both cell population-
based and individual cell-based analyses to observe the effect of polyanhydride 
chemistry on DCs. While both of these techniques have been used individually in 
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previous studies focused on particulate adjuvants22,25,29-38,44, to our knowledge, 
this is the first time the analyses have been coupled to enhance our 
understanding of DC activation exploited by nanoparticles. The knowledge 
gained from incorporating the results determined by flow cytometry, cytokine 
analysis, and fluorescent microscopy showed many interesting trends based on 
polyanhydride chemistry. 
Very hydrophobic nanoparticles (poly(CPH)) induced cell death, which 
was witnessed in all analyses. Poly(CPH) nanoparticle agglomerates drastically 
reduced the population of viable cells shown by flow cytometry and induced high 
levels of cytokine secretion. Also, the few cells present in microscopy had very 
rounded morphologies, which is a characteristic of unhealthy cells. The 
hydrophobicity of poly(CPH) nanoparticles is more than likely causing strong 
inflammatory insult to the dendritic cells pushing them towards cell death. This is 
supported by the very high levels of cytokines (Fig. 5.5), especially TNF-α, 
secreted from DCs incubated with poly(CPH) nanoparticles. TNF-α is a pro-
inflammatory cytokine that can cause cell death and inflammation.49 While small 
amounts may be beneficial in the initiation of an immune response, too much can 
initiate a cytokine storm causing significant tissue damage. DCs incubated with 
poly(CPH) nanoparticles produced half the amount of TNF-α generated by LPS, 
an endotoxin, which is known for stimulating a strong inflammatory response in 
vivo.50 The cytokine production upon stimulation by poly(CPH) nanoparticles was 
~15-fold that of cells incubated with 50:50 CPH:SA nanoparticles and ~75-fold 
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that of cells given no stimulus. This behavior makes poly(CPH) nanoparticles a 
poor choice as a vaccine adjuvant. 
Moderately hydrophobic agglomerates (50:50 CPH:SA and 50:50 
CPTEG:CPH) induced moderate cytokine secretion. While they did not induce 
cytokine production as strongly as poly(CPH) nanoparticle agglomerates, these 
chemistries were able to induce cytokine secretion greater than no stimulus and 
less hydrophobic agglomerates (poly(SA) and poly(CPTEG)). In microscopy 
analysis, these two chemistries displayed similar size v count plots after 2 h (Fig. 
5.8) and showed lysosomal-associated agglomerates persisting at 48 h (Fig. 
5.7). The rapid internalization and persistence of these particles may be seen as 
a stress by the DCs, inducing cytokine production.51 The capacity for 
nanoparticles of these chemistries to persist even in the strongly degradative 
environment of the lysosome indicates their long-term delivery potential. 
The least hydrophobic agglomerates (poly(SA), 50:50 CPTEG:CPH, and 
poly(CPTEG)) induced increased cell surface marker expression. CD209 
expression was enhanced for all three chemistries whereas MHC I, MHC II, 
CD40 and CD86 was enhanced for only poly(SA) and 50:50 CPTEG:CPH. The 
microscopy data shows that these three chemistries were all able to be 
significantly broken down causing fluorescent payload release by 48 h whereas 
all other chemistries were not. The inability for poly(CPTEG) nanoparticle 
agglomerates to initiate any cell surface marker other than CD209 may be due to 
rapid degradation and a low number of internalized agglomerates. The 
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mechanism by which CD209 expression could be enhanced by particles is still 
not well characterized. The behavior of poly(CPTEG) nanoparticle aggregates 
intracellularly indicates that CD209 activation may occur more quickly or by a 
different mechanism than the expression of other cell surface markers. Further 
experiments are necessary to better understand CD209 activation by 
nanoparticle aggregates. The enhanced cell surface marker expression of MHC 
I, MHC II, CD40 and CD86 correlates well to the intracellular behavior of 
poly(SA) and 50:50 CPTEG:CPH nanoparticle agglomerates. DC activation 
based on successful processing of internalized material would agree with 
accepted antigen presenting cell activation behavior.52 The specific nature of 
enhanced cell surface marker expression also appears to corroborate the 
intracellular behavior. Nanoparticle agglomerates of poly(SA) appear to be 
degrading and releasing payload within the cytosol due to the diffusive presence 
of FITC-dextran similar to previous research.53 The ability to release payload in 
the cytosol could cause cross presentation  through the endogenous pathway. 
Fig. 5.4 clearly shows enhanced MHC I expression for DCs exposed to poly(SA) 
nanoparticles which would correspond to this mode of activation. In contrast, the 
many dim 50:50 CPTEG:CPH nanoparticle agglomerates appear to release their 
fluorescent payload , but persist in lysosomal compartments. This behavior 
corresponds with the lower MHC I expression for DCs incubated with this 
chemistry. With chemistry-dependent modulation of DC activation, combination 
vaccines could be used for activation of both the Th1 and Th2 response. This 
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flexibility allows for the nanovaccine platform to be tailored for a wide range of 
emerging and re-emerging pathogens. 
 
5.6 Conclusions 
  
 Polyanhydride nanoparticles are promising candidates for vaccine delivery 
applications. This data clearly demonstrates that polymer chemistry affects their 
interactions with DCs. Nanoparticle hydrophobicity was the strongest correlating 
property to DC behavior. Incubating DCs with highly hydrophobic nanoparticles 
induced cell death, but incubation with the least hydrophobic nanoparticles 
initiated the expression of only CD209. There appears to be a hydrophobicity 
continuum that is dictated by polymer chemistry and can be tailored to initiate 
desired DC responses. 50:50 CPTEG:CPH nanoparticles had the unique 
behavior of releasing some payload while persisting in Lamp-1+ vesicles as large 
aggregates. This was the only polymer chemistry able to enhance both cell 
surface marker expression and cytokine secretion. From long-lasting particle 
persistence to cytosolic delivery, the variance in initiated responses bodes well 
for the use of these materials as a nanovaccine platform. 
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6.1 Abstract 
 
This chapter focuses on the development and evaluation of degradable 
polyanhydride nanoparticles as a single dose vaccine-platform. Despite the 
successes provided by vaccination, many challenges still exist with respect to 
controlling new and re-emerging infectious diseases. Innovative vaccine 
platforms composed of adaptable adjuvants able to appropriately modulate 
immune responses, induce long-lived immunity in a single dose, and deliver 
immunogens in a safe and stable manner via multiple routes of administration 
are needed. This work describes the development of a novel biodegradable 
polyanhydride nanoparticle-based vaccine platform administered as a single 
intranasal dose that induced long-lived protective immunity against respiratory 
infectious diseases using Yesinia pestis, the causative agent of pneumonic 
plague, as a model pathogen. The polymer system used was the 50:50 
copolymer of poly((1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane)-co-(1,6-bis(p-
carboxyphenoxy)hexane)) (CPTEG:CPH). This formulation was chosen since it 
possesses stable and extended release kinetics as well as superb APC 
stimulation properties. F1-V, a fusion protein antigen of Yersinia pestis, was 
delivered solubly and encapsulated within nanoparticles in a single-dose 
intransally. Relative to the responses induced by the recombinant protein F1-V 
alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen 
induced an immune response that was characterized by high titer and high 
avidity IgG1 antibody specific for F1-V and persisted for at least 23 weeks post-
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vaccination. No bacteria were recovered from the lungs, livers, or spleens of 
mice vaccinated with the nanoparticle-based formulation and histopathological 
appearance of lung, liver, and splenic tissues from these mice post-vaccination 
was remarkably similar to uninfected control mice. 
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6.2 Introduction 
 
 Natural infections with pathogens stimulate protective and lasting antibody 
responses because they induce affinity maturation of B cells, a process by which 
B cells produce antibodies with an increased affinity for antigen during the course 
of an immune response1. Vaccines have been designed to mimic the immune 
response associated with an active infection yet avoid the undesirable effects of 
disease. By employing a priming dose followed by two to three booster doses, 
modern vaccine regimens facilitate the process of affinity maturation, which 
occurs with repeated or sustained exposure to the same antigen1. Vaccines also 
utilize adjuvants to improve immunogenicity by providing pro-inflammatory 
signals and prolonging the persistence of vaccine antigens2. Unfortunately, 
current adjuvants approved for human use are not tunable and, as many 
pathogens have evolved to evade the host immune response, currently available 
vaccine strategies may not provide adequate induction of long-lived protective 
immunity. Development of single-dose, tailored nano-adjuvant platforms will not 
only provide an effective means to induce protective immunity, but will also allow 
production of cost-effective vaccines that can reduce the need for multiple 
injections and result in greater patient compliance. Moreover, these novel 
technologies will obviate the need for hypodermic needles and professionals to 
administer the vaccine. In this regard, implementation of vaccine delivery 
systems based on biodegradable polymers offers significant advantages for 
immunization regimens.  
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 In order to enhance vaccine efficacy and induce long-term, protective 
immunity, the choice of route (intramuscular3,4, subcutaneous5,6 or intranasal4,7), 
adjuvant (Alhydrogel5,6, viral vectors3, polyester microparticles4, or lipid A 
mimetics7), and vaccination schedule (single-dose4,5,7 or multiple-doses3,6) must 
all be considered. For respiratory pathogens such as Yersinia pestis, intranasal 
vaccination offers many advantages over parenteral vaccination, including ease 
of administration and ability to enhance both mucosal and systemic immune 
responses8. While the rapid induction of protection is critical, the ability of vaccine 
formulations to induce long-lasting protection characterized by high-avidity 
antibody is equally important1. Y. pestis, the causative agent of plague, is a 
Category A agent (http://www.bt.cdc.gov/agent/agentlist-category.asp) to which 
there is no vaccine currently in production. The pursuit of a protective plague 
vaccine has evolved from the use of killed whole-cell9 and live-attenuated 
bacteria10 to recombinant proteins such as caf1 (i.e., F1) and LcrV (i.e., V)3,5,7. In 
addition, immunization with the fusion protein, F1-V, provides protection in mice5 
and cynomolgus macaques6; however, it has been less successful in other non-
human primate models such as the African green monkey11. To date, only lipid A 
mimetic adjuvants have been shown to provide long-term, protective immunity 
against lethal Y. pestis challenge7. 
 Multiple biodegradable polymers, including polyesters, have been studied 
as vaccine delivery vehicles4,12. By comparison, the controlled release and 
adjuvanticity provided by novel polyanhydride carriers, first pioneered by Robert 
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Langer of MIT in the 1980s, allows for immune system activation, reduction of 
antigenic dose, prolonged antigen exposure, stability of the encapsulated protein 
antigen, and immune modulation13-22. The results presented herein demonstrate 
that encapsulation of F1-V into polyanhydride nanoparticles administered as a 
single intranasal dose successfully induced long-term protection against Y. pestis 
that correlated with a high titer, high avidity F1-V-specific antibody response. 
 
6.3 Materials and Methods 
 
6.3.1 Materials 
  
 4-hydroxybenzoic acid (96%), 1-methyl-2-pyrrolidinone anhydrous 
(99.5%), 1,6-dibromohexane (98.5%), triethylene glycol (99%), N,N-
dimethylacetamide (99.8%) and monophosphoryl lipid A (MPLA) were purchased 
from Sigma-Aldrich (Milwaukee, WI). 4-p-fluorbenzonitrile was purchased from 
Apollo Scientific (Stockport, Cheshire, England). All other chemicals used for 
synthesis and particle precipitation were purchased from Fisher Scientific 
(Pittsburgh, PA) and used as received. F1-V was obtained from the NIH 
Biodefense and Emerging Infection (BEI) Research Resources Repository 
(Manassas, VA). The following reagent was also obtained through the NIH BEI 
Research Resources Repository: Yersinia pestis, Strain CO92, NR-641. 
 
6.3.2 Polymer Synthesis and Characterization 
  
 Synthesis of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) diacids was accomplished following 
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previously established methods.23 Melt polycondensation of 50:50 CPTEG:CPH 
copolymer was carried out under vacuum (0.3 mm Hg) for 90 minutes at 140 °C. 
The resulting polymers were dissolved in deuterated chloroform (Cambridge 
Isotope Laboratories, Andover, MA) to characterize polymer structure by 1H 
nuclear magnetic resonance (NMR) on a Varian VXR 300 MHz spectrometer 
(Varian Inc., Palo Alto, CA).  The NMR spectra confirmed the synthesis of the 
desired copolymer composition. In addition, gel permeation chromatography 
(Waters HPLC System, Milford, MA using Varian Inc. GPC columns) and 
differential scanning calorimetry (Auto Q20, TA Instruments, New Castle, DE) 
were utilized to measure molecular weight and glass transition temperature, 
respectively. The 50:50 CPTEG:CPH copolymer had a Mn of 8500 Da, PDI of 
1.70, and a Tg of 13 °C. All data was consistent with previously published work.23 
 
6.3.3 Nanoparticle Design 
  
 Both F1-V encapsulated and blank nanoparticles were fabricated by the 
polyanhydride anti-solvent nanoencapsulation (PAN) method modified from the 
protocol reported in Ulery et al.18 Polymer was dissolved in methylene chloride at 
0 °C at a concentration of 20 mg/mL. For encapsulat ed nanoparticles F1-V was 
sonicated for 15 s at a concentration of 2% of total batch weight to form a 
suspension. The polymer/antigen solution was rapidly poured into a bath of 
pentane held at -20 °C at an anti-solvent to solven t ratio of 80:1. Penetration of 
anti-solvent into the polymer solution microenvironment caused spontaneous 
nanoparticle formation; the particles were subsequently filtered by Whatman No. 
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50 paper filters in a Buchner funnel. This procedure yielded a fine powder with at 
least 70% recovery and a F1-V encapsulation efficiency greater than 94%. 
Nanoparticle morphology was investigated using scanning electron microscopy 
(SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan). Quasi-elastic light scattering 
(QELS) was employed to determine nanoparticle size (Zetasizer Nano, Malvern 
Instruments Ltd., Worchester, UK).  
 In vitro release kinetics of the F1-V antigen were measured by suspending 
nanoparticles (12.5 mg) in 1 mL of 0.1 M phosphate buffer (pH 7.4) at 37 °C and 
agitated at 100 rpm. Sodium azide (0.01 % w/w) was added to prevent microbial 
contamination. At different time points, samples were centrifuged (10,000 rpm for 
5 min) and aliquots of 750 µL of supernatant were collected and replaced with 
fresh buffer. Supernatants were stored at 4 °C unti l they were studied by micro 
bicinchoninic acid (micro BCA) assay (Thermo Scientific, Rockford, IL). After 70 
days of release, the remaining nanoparticles were analyzed for non-released 
protein the nanoparticles were suspended in 3 mL of 17 mM sodium hydroxide 
(Fischer Scientific, Hampton, NH). The solution was withdrawn by syringe and 
loaded into a dialysis cassette (Slide-A-Lyzers 3,500 MWCO, Pierce 
Biotechnology Inc., Rockford, IL). The cassette was placed in 800 mL of 17 mM 
sodium hydroxide solution and incubated at 100 rpm and 37 °C for one week in 
order to catalyze the degradation of any remaining polymer. After incubation, the 
protein solution was removed by syringe and quantified by the micro BCA assay. 
Total protein encapsulated was determined by adding the quantity of protein 
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released during the experiment to the quantity of protein extracted from 
remaining nanoparticles17.  Cumulative release profiles were generated by 
normalizing the data against the total amount of encapsulated protein and 
reported as fractional protein release. 
 
6.3.4 Animal Vaccinations 
 
 Adult female mice, strain C57BL/6, at least 8 weeks of age were used for 
all experiments. Mice were obtained from JAX® Breeding and Colony 
Management Services (Jackson Laboratory, Bar Harbor, ME). The mice were 
maintained under SPF condition with all bedding, cages, water, and feed 
sterilized prior to use. Animal procedures were undertaken with approval from 
either the Iowa State University or the Albany Medical Center Committees on 
Animal Care and Use. 
 Mice were first anesthetized by i.p. injection of 100 µL of 80 mg kg-1 
ketamine (KetaVed®, Vedco Inc. St. Joseph, MO) and 16 mg kg-1 xylazine 
(Phoenix Scientific, St. Joseph, MO) diluted in sterile phosphate buffered saline 
(pH 7.4, PBS). After confirming that the mice were completely anesthetized, 40 
µL of vaccine (50 µg of F1-V in each dose) was delivered intranasally. Solutions 
containing nanoparticles (500 µg) were sonicated prior to use and held at 0 °C. 
All vaccine solutions were vortexed immediately prior to each administration. 
Mice were monitored for signs of deep respiration during vaccination and until 
they were fully awake. Blood samples were drawn from the saphenous vein at 3, 
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6, 9, 12, 15, 18, and 23 weeks post-vaccination. Sera was isolated and stored at 
-20 °C until assayed for anti-F1-V specific antibod ies. 
 
6.3.5 F1-V Specific Enzyme-Linked Immunosorbent Assay (ELISA) 
 
 High protein binding 96-well Costar microtiter plates (Corning Life 
Sciences, Lowell, MA) were coated overnight with 100 µL PBS containing 0.5 
µg/mL F1-V. Plates were blocked for at least 2 h at room temperature with PBS 
containing 0.05 % Tween 20 (PBS-T) and 2.5 % skim milk as a blocking agent 
(Nestle, Glendale, CA). PBS-T was used to rinse the plates three times to 
remove any unbound blocking reagent. Sera samples from individual mice were 
diluted 1:200, added to the wells and then serially diluted three-fold in PBS-T with 
1% goat serum and refrigerated overnight (at least 12 h) at 4 °C.  PBS-T was 
used to wash plates three times followed by the addition of 100 µL of PBS-T with 
1% goat serum containing alkaline phosphatase-conjugated goat anti-mouse 
IgG(H&L) (Jackson Laboratory) at 1 µg/mL. After 2 h of incubation, the microtiter 
plates were washed with PBS-T three times followed by the addition of 100 µL of 
sodium carbonate (50 mM) and magnesium chloride (2 mM) buffer (pH 9.3) 
containing 1 mg/mL phosphatase substrate (Sigma 104, Sigma-Aldrich, St. 
Louis, MO) and reacted at room temperature for 30 min. Optical density (OD) of 
each well was measured at 405 nm using a Spectramax 190 Plate Reader 
(Molecular Devices, Sunnyvale, CA). For this experiment, endpoint titers were 
defined as the greatest dilution where optical density was still at least twice that 
of the average optical density of normal mouse serum (1:1800). 
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 Antibody avidity analysis was performed as described previously.15 
Individual serum samples (1:200) were placed into 16 replicate wells of a 
microtiter plate previously coated with F1-V as described above. Following the 
wash step to remove unbound serum antibodies, 150 µL of 0.1 M sodium 
phosphate containing sodium thiocyanate (a chaotropic agent) was added to 
duplicate wells in increasing concentrations from 0 to 5 M. The plates were 
incubated for 15 min at room temperature and then washed five times with PBS-
T followed by the addition of alkaline phosphatase-conjugated goat anti-mouse 
IgG(H&L) as described above. Avidity index was defined as the concentration of 
sodium thiocyanate necessary to reduce the OD reading by 50% compared to 
wells treated with 0.1 M sodium phosphate. This was accomplished by fitting an 
exponential curve to a plot of OD versus sodium thiocyanate concentration. 
 
6.3.6 Y. pestis Challenge, Bacterial Burden, and Histopathology 
 
 Y. pestis CO92, (NR-641, Biodefense and Emerging Infection Resources, 
Manassas, VA) and was handled in a Class-II biological safety cabinet in a CDC 
certified animal biosafety level-3 suite at Albany Medical College. Y. pestis CO92 
organisms were grown O/N at 37 °C in heart-infusion  broth supplemented with 
0.2 % D-galactose. Vaccinated mice were anesthetized as mentioned earlier, 
and challenged intranasally with 850 CFU (LD100) of Y. pestis in 20 µL 
PBS/mouse at 6 or 23 weeks post-vaccination. For vaccine efficacy studies, 
infected mice were observed for 14 days post-challenge for their survival. For 
bacterial organ burdens, lungs, livers, and spleens were collected at 6 weeks 
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post-vaccination and homogenized in one mL of PBS in mini-beadbeater 
(BioSpec Products Inc., Bartlesville, OK) at 72 h post-infection. Organ 
homogenates were diluted ten-fold in PBS and 10 or 100 µL of homogenates 
were plated on to Congo red (CR) agar plates. Y. pestis colonies were 
enumerated after 48 h of incubation of CR agar plates at 28 ºC. Bacterial 
burdens were expressed as log10 means of CFU ± standard errors of the means 
for three mice per group. To determine if vaccines generated immunity is 
sterilizing, bacterial organ burdens were done on the completion of survival 
observation period, i.e., 14 days post-infection on 6 weeks and 23 weeks post-
vaccination trials. For histopathological studies, vaccinated and infected mice 
were sacrificed using pentobarbital sodium (100 mg kg-1) and lungs, livers, and 
spleens were collected at different time points after infection and fixed in 10% 
buffered formalin for 7 days. The sterility of formalin-fixed organs was confirmed 
before further tissue processing. Tissues were paraffin-embedded and their 5-µM 
sections cut and mounted on glass slides and later stained with hematoxylin and 
eosin. Photomicrographs of tissue sections were acquired and analyzed using 
cellSens™ standard software (version 1.3, Olympus Corporation, Japan) on 
Olympus BX-41 light microscope equipped with Olympus microscope digital 
camera DP72. All photomicrographs were resized and converted to CMYK profile 
in Adobe Photoshop CS2 (Adobe Systems Incorporated, USA). Tissues were 
analyzed histopathologically for evidence of inflammation, hemorrhage, edema, 
necrosis, changes in tissue architecture, and bacteria. 
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6.3.7 Statistical Analysis 
 
Analysis of survival was done by Mantel-Cox log rank test and all other 
statistical analysis was completed utilizing two-tailed t-tests. All statistical 
analysis was performed using GraphPad Prism 5 software (San Diego, CA). 
 
6.4 Results 
 
6.4.1 Nanoparticle Characterization 
 
 We have previously shown that F1-V encapsulated into amphiphilic 
polyanhydride particles based on 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (Fig. 6.1) successfully 
preserved the antigenicity of F1-V upon release.24 SEM images of blank (Fig. 
6.2a) and 2% F1-V loaded 50:50 CPTEG:CPH nanoparticles (Fig. 6.2b) show 
similar spherical morphology and size regardless of antigen loading. QELS 
analysis (Fig. 6.2c) demonstrated that antigen encapsulation did not change 
nanoparticle size (204 nm vs. 196 nm). It is known that 70-95% of aerosolized 
nanoparticles (50–200 nm) will deposit deep within the lung.25 The ability for 
encapsulated F1-V to be gradually released over time from nanoparticles is 
shown in Fig. 2d. Antigen release was monitored for 70 days and showed a low 
initial burst (9%), approximate zero order release through 28 days, and near 
complete release (93%) by 70 days. 
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Figure 6.1. Chemical structure of a random CPTEG:CPH copolymer. 
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 (a) 
 
 (b) 
 (c) 
 
 (d) 
 
Figure 6.2. Material properties of 50:50 CPTEG:CPH nanoparticles. 
Representative SEM images of (a) blank and (b) 2% F1-V loaded 50:50 
CPTEG:CPH nanoparticles (scale bar = 1 µm). (c) Particle size distribution as 
determined by QELS for blank (204 ± 62) and 2% F1-V loaded 50:50 
CPTEG:CPH nanoparticles (196 ± 77) with n = 3. (d) In vitro cumulative release 
of F1-V from 50:50 CPTEG:CPH nanoparticles in pH 7.4 PBS analyzed by micro 
bicinchoninic acid assay (n = 2, representative of two separate nanoparticle 
batches). 
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6.4.2 Protection Against Live Y. pestis Challenge 
 
 To examine the effectiveness of antigen-encapsulated nanoparticles as 
intranasal, single-dose vaccines, C57BL/6 mice were vaccinated according to the 
regimens provided in Table 6.1. 
 
Table 6.1. Vaccination regimens employed in this study. 
 
Experimental 
Group 
Soluble           
F1-V (µg) 
Encapsulated 
F1-V (µg) 
50:50 CPTEG:CPH 
Nanoparticles (µg) MPLA (µg) 
          
S50 50 ----- ----- ----- 
S50 + MPLA 50 ----- ----- 10 
          
S50 + E0 50 ----- 500 ----- 
S40 + E10 40 10 500 ----- 
 
* Quantities indicate the amounts of immunogen or adjuvant delivered to each 
mouse in the indicated group. S = soluble protein; E = encapsulated protein. The 
subscripts indicate the amount of soluble or encapsualted protein (in µg) 
administered per dose. 
 
To study the capacity of the vaccine regimens to provide short-term and long-
term protection against pneumonic plague, mice were intranasally challenged at 
6 weeks or 23 weeks post-vaccination with 850 CFUs of Y. pestis CO92. At 6 
weeks post-vaccination (Fig. 6.3a), none of the mice in the S50 treatment group 
survived the challenge whereas 80% (4/5) of mice treated with S50 + MPLA and 
40% (2/5) of mice treated with S50 + E0, survived. In contrast, all mice (5/5) 
treated with S40 + E10 survived. When challenged at 23 weeks post-vaccination 
(Fig. 6.3b), only 12.5% (1/8) of mice treated with S50 + MPLA and 25% (2/8) of 
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mice treated with S50 + E0 survived challenge, in comparison to 100% survival of 
the mice (7/7, p < 0.007) vaccinated with S40 + E10.  
 
 
 
(a) 
 
 
 
(b) 
 
Figure 6.3. Impact of vaccination on the survival of C57BL/6 mice challenged 
with Y. pestis CO92. Mice were intranasally challenged with 850 CFU (LD100) Y. 
pestis CO92 at (a) 6 weeks post-vaccination (n = 5 per group) or (b) 23 weeks 
post-vaccination (n = 7 per group). * = p < 0.007, # = p < 0.001 and + = p < 
0.0001. 
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The efficacy of these vaccines for preventing bacterial replication in lungs, 
livers, and spleens at 72 h post-infection was determined (Fig. 6.4a). Bacterial 
burdens in lungs, livers, and spleens were consistent with survival of vaccinated 
mice (Fig. 6.3a) and IgG titers (Fig. 6.7a) and histopathology (Fig. 6.5 and Fig. 
6.6). The S50 + MPLA vaccine regimen was able to reduce the bacterial burdens 
in lungs, livers, and spleens, but failed to generate effective long-term immunity 
(Fig. 6.3b). 
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 (a) 
 
 (b) 
 
Figure 6.4. Bacterial burden and histopathology analysis of vaccinated mice. (a) 
CFU of Y. pestis CO92 at 72 h post-infection in the lungs, livers, and spleens of 
C57BL/6 mice (n = 3 per group) that were vaccinated 6 weeks prior to challenge. 
(b) Photomicrographs of lung sections from mice: uninfected and unvaccinated (i) 
and challenged 6 (ii, iii, and iv) and 23 (v) weeks post-vaccination. S50 vaccinated 
mice, 72 h post-challenge (ii) showed severe pathology and loss of tissue 
architecture due to overwhelming bacterial multiplication in lungs (arrows), 
neutrophilic infiltration (arrowhead), hemorrhage (+), edema (asterisks), and 
necrosis. Bronchioles had bacteria clumped with fibrin deposits and neutrophils. 
Absence of lung pathology was seen in S40 + E10 vaccinated mice at 72 h (iii), 14 
days (iv), and 21 days post-challenge (v). Av - alveolus, Br - bronchiole, Pa - 
pulmonary artery, Pv - pulmonary vein. Magnification is 400X. Scale bar = 50 µm. 
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No bacteria were recovered from the lungs, livers, or spleens of mice treated with 
S40 + E10 (Fig. 6.4a). Regardless of vaccination regimen, no bacteria were 
detected in lungs, livers, and spleens of mice that survived to day 14 post-
infection in both the 6- and 23-week experiments, correlating with vaccination 
efficacy. Nanoparticle-based vaccines also prevented tissue pathology (Fig. 6.4b, 
Fig. 6.5 and Fig. 6.6). The mice treated with S40 + E10, when challenged 6 weeks 
post-vaccination, did not develop pathology in lungs (Fig. 6.4b iii and Fig. 6.5 v), 
livers (Fig. 6.5 x), and spleens (Fig. 6.5 xv) 72 h post-infection due to their ability 
to clear bacteria and likely control inflammation. At the end of the survival 
observation periods in both challenge experiments, histological examination of 
the lungs from survivors (Fig. 6.6) treated with S40 + E10 showed no evidence of 
lesions and was remarkably similar to uninfected control mice (Fig. 6.2d i and 
Fig. 6.5 i). 
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Figure 6.5. Histopathological analysis of lungs, spleens, and livers of control and 
vaccinated mice 6 weeks post-vaccination at 72 h post-challenge. 
 
Lungs: Three out of three S50 vaccinated mice (ii) lost normal lung architecture 
due to bacterial multiplication (arrow), neutrophilic infiltrations (black arrowhead) 
within tissues and bacterial colonies, as well as edema (asterisk), hemorrhages, 
and necrosis. Similar pathology was also seen in S50 + E0 vaccinated mice (iv), 
although to a lesser extent and with the presence of lymphocytic infiltrations 
(yellow arrowhead). S50 + MPLA vaccinated mice (iii) did not show multiplying 
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bacteria, but had mixed lymphocytic and neutrophilic infiltrations in lung 
parenchyma. Lungs of S40 + E10 vaccinated mice (v) were free of any pathology 
or bacterial colonies and were remarkably similar to unimmunized and uninfected 
lungs of control mice (i). 
 
Spleens: S50 vaccinated mice (vii) had bacterial colonies multiplying in spleens 
(arrow), neutrophilic (black arrowhead) and lymphocytic (yellow arrowhead) 
infiltrations, edema (asterisk) and necrotic cells (+) in the red pulp and marginal 
zone. There was also reduction in size of the follicle as well as the marginal zone 
(data not shown). S50 + MPLA vaccinated mice (viii) had neutrophilic infiltrates in 
the red pulp. S50 + E0 vaccinated mice (xi) also had edema, necrotic cells, and 
neutrophilic infiltrates in the red pulp. No bacteria, necrosis or edema were 
present in S40 + E10 (x) vaccinated mice and histology was similar to healthy 
spleen tissue (vi). 
 
Livers: Bacterial colonies (arrow) are visible in a liver of S50 vaccinated mouse 
(xii) with neutrophilic (black arrowhead) and lymphocytic (yellow arrowhead) 
infiltrates in liver parenchyma. Although bacteria were present, neutrophilic 
infiltration was not as severe as seen in lungs of S50 vaccinated mice. 
Degenerative changes were also seen in the cytoplasm of the hepatocytes of S50 
vaccinated mice. S50 + MPLA vaccinated mice (xiii) also had degenerative 
changes in the hepatocytes and loosely packed cells were present that mostly 
included lymphocytes and neutrophils. S50 + E0 vaccinated mice (xiv) had similar 
hepatic degeneration with loosely packed cells that mostly included neutrophils. 
S40 + E10 vaccinated mice (xv) did not show any pathology like control mice (xi). 
 
The absence of pathology in lungs, spleens and livers of S40 + E10 vaccinated 
mice indicates that nanoparticle-based vaccine can be used to protect mice from 
Y. pestis induced tissue damage. 
 
Av-Alveoli, F - Follicle, Mz - Marzinal zone, and RP - Red pulp. Objective lens 
magnification is 100X. Scale bar = 20 µm. 
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Figure 6.6. Histopathological analysis of lungs from mice 23 weeks post-
vaccination at 14 days post-challenge. Protected mice had similar lung histology 
to that of uninfected mice (Supplementary Fig. 1i). Av- Alveoli. Objective lens 
magnification is 100X, Scale bar = 20 µm. 
 
 
6.4.3 Characterization of Antibody Response 
 
 To further characterize the protective immune response, serum samples 
collected at 3, 6, 9, 12, 15, 18, and 23 weeks post-vaccination were analyzed for 
anti-F1-V IgG titers (Fig. 6.7a). Prior work has shown that high antibody titers 
correlate to protection against live Y. pestis challenge.3-8,12 Mice vaccinated with 
S50 generated low levels of antibody that is in agreement with previous studies 
evaluating intranasally delivered Y. pestis antigens.7 At 3 weeks post-
vaccination, all mice treated with adjuvanted formulations induced demonstrable 
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titers. Beyond 3 weeks, the anti-F1-V IgG response waned in the mice treated 
with S50 + MPLA and S50 + E0 while the F1-V- specific IgG response in the S40 + 
E10 vaccinated mice was sustained for at least 23 weeks (Fig. 6.7a). The results 
also demonstrate that IgG1 was the dominant antibody subtype produced (Fig. 
6.7b). In this regard, it has been shown that F1 and V antigen-specific IgG1 
facilitates APC phagocytosis and blocks the Y. pestis type III secretion system, 
respectively.26  
 Serum samples were also analyzed for the avidity of the anti-F1-V IgG 
produced to characterize the affinity maturation of the antibody response (Fig. 
6.7c). Others have shown for other bacteria (e.g., Streptococcus pneumonia) that 
poor antibody avidity correlated to a lack of protection.27 Average relative avidity 
of the F1-V-specific IgG was found to be low in the mice treated with S50, S50 + 
MPLA, and S50 + E0 formulations at all time points. In contrast, mice vaccinated 
with S40 + E10 generated higher avidity anti-F1-V specific IgG at 3-weeks post-
vaccination, which increased by 6 weeks post-vaccination and was sustained 
through 23 weeks post-vaccination (Fig. 6.7c). 
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(a) 
 
(b) 
 (c) 
 
Figure 6.7. Assessment of anti-F1-V antibody response. (a) Kinetics of the IgG 
antibody titer for each of the treatments over 23 weeks post-vaccination. (b) 
Antibody isotype induced by various immunization regimen. Optical density was 
determined by ELISA at a 1:1000 dilution. (c) IgG antibody avidity through 23 
weeks post-vaccination. Avidity was analyzed by ELISA at a 1:200 dilution. Data 
is presented as the mean ± SEM (n = 7 per group). * = p < 0.02, # = p < 0.005 
and + = p < 0.0001 (compared to S50 + MPLA). 
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6.5 Discussion 
 
  These results demonstrate that single-dose intranasal administration of 
nanovaccines consisting of soluble F1-V together with F1-V encapsulated into 
polyanhydride nanoparticles (S40 + E10) was able to induce significant, long-lived 
antibody titers with high avidity that correlated to long-term protection against a 
lethal Y. pestis challenge. When this result is compared to the immunostimulatory 
behavior of soluble F1-V administered with blank nanoparticles (S50 + E0), it is 
clear that the presence of antigen-encapsulated nanoparticles is critical to the 
induction and maintenance of long-lived, high-avidity IgG1 antibody and 
protection from live challenge. Formulations with both soluble and encapsulated 
antigen performed the dual functions of enabling the soluble antigen to initiate a 
primary response28 and the antigen-encapsulated nanoparticles to provide 
sustained (or persistent) antigen delivery that maintains antibody titer and 
dramatically increases the affinity maturation of the antibody response.29  
 While in vivo mechanisms that govern nanoparticle-mediated 
enhancement of immune responses have yet to be elucidated, recent research 
showed that the activation of complement pathways and antigen presenting cells 
plays a key role in how some nanoparticles activate an immune response.30 The 
capacity for polyanhydride nanoparticle formulations to induce activation16,18,31 of 
pulmonary DCs and alveolar macrophages in vivo could partially explain their 
adjuvant capabilities and induction of protective immunity observed in the present 
work. Activated DCs will traffic to the draining lymph node where they have a 
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myriad of interactions that facilitate the adaptive immune response.28 According 
to studies by Jenkins, activated DCs and soluble antigen work in concert to 
stimulate the clonal expansion of antigen-specific lymphocytes.28 The importance 
of adequate soluble antigen during the initiation of the immune response and the 
consequent processing and presentation by resident DCs would explain why 
vaccine regimens employing only antigen-encapsulated nanoparticles were 
unable to initiate a robust immune response (data not shown). Thus, the 
nanoparticle-based formulations clearly functioned as adjuvants because they 
initiated a robust immune response, provided extended antigen delivery, and 
induced long-term protection against infection. 
 The potential for extended antigen delivery by 50:50 CPTEG:CPH 
nanoparticles can be attributed to their presence in the lungs 28 days post-
intranasal vaccination using in vivo imaging (data not shown). While 
nanoparticles have been shown to activate and be internalized by APCs in 
vitro16,18, the ability for some particles to evade short-term clearance by 
professional phagocytes would allow for prolonged antigenic exposure because 
of delayed APC internalization, gradual polymer degradation and release of 
antigen, or a combination thereof. Prior research shows that vaccines delivered 
with an adjuvant via multiple doses are able to induce high avidity antibody.32,33 
More mechanistic studies provide evidence that continual presentation of antigen 
by adjuvants specifically conveys increased avidity.34 This observation is 
generally attributed to somatic hypermutation and affinity maturation that occurs 
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in the germinal centers of lymphoid organs.35 Clearance avoidance and delayed 
degradation of nanoparticles would provide a mechanism by which presence of 
an antigen could be prolonged resulting in the induction of antigen-specific 
antibody responses with higher titer and avidity. 
 
6.6 Conclusions 
 
 To our knowledge, the performance of the polyanhydride nanoparticle-
based formulations in this work is the first demonstration of the ability of particle-
based vaccines to induce long-term protection against lethal challenge after a 
single vaccination. Using polyanhydride microparticle-based adjuvants, mice 
vaccinated intramuscularly with a single dose formulation consisting of soluble 
tetanus toxoid (TT) together with TT-encapsulated particles demonstrated long-
lived antibody titer with high avidity, providing yet another example of the 
capability of the particle-based vaccines to function in a single dose.15 In addition, 
the nanovaccine platform technology described here can function as effective 
adjuvants for a wide range of antigens. For example, in the case of seasonal 
diseases like influenza, for which immune protection needs to last for six months, 
particle-based formulations can be designed to encapsulate multiple payloads 
and provide effective immunity with a single administration. The versatility of the 
polyanhydride chemistry and the scalability of the particle fabrication process 
enable the design of combination vaccines with cocktails of microparticles and 
nanoparticles of different chemistries delivered via one or more routes. The 
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design and development of customized polyanhydride particle-based vaccines 
can lead to a highly effective technological platform for vaccine delivery. 
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CHAPTER 7 
 
Conclusions & Future Research   
 
7.1 Conclusions 
 
 With aluminum salts being the only adjuvant utilized in the U.S. for human 
vaccines, their limitations (unidirectional immune modulation, delivery route 
issues, and capacity to induce inflammatory myopathy)1 necessitate the 
development of novel vaccine adjuvants. Also, intranasal delivery of vaccines 
holds promise of reducing vaccine dose and administration time while 
vaccinating the host mucosally and systemically as evidenced with the intranasal 
flu vaccine, FluMist®.2 The adjuvant capabilities and deep lung tissue depositing 
size of polyanhydride nanoparticles make them a promising nanovaccine 
platform. The ability to reproducibly fabricate CPH:SA nanoparticles and their 
chemistry-dependent effect on particle and soluble antigen uptake by THP-1 
human monocytes was investigated in this thesis (Chapter 4) to better 
understand the role chemistry plays in immune activation. This analysis was 
expanded upon in Chapter 5 when both individual cell based (fluorescent 
microscopy) and cell population based (flow cytometry and multiplex-bead assay) 
techniques were utilized to determine more complex antigen presenting cell 
activation effects of both CPH:SA and CPTEG:CPH nanoparticles on murine 
bone-marrow derived dendritic cells. This research showed a unique, pathogen-
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like behavior of 50:50 CPTEG:CPH nanoparticles that correlated to both 
increased cell surface marker expression and cytokine secretion. To evaluate the 
adjuvanticity of 50:50 CPTEG:CPH nanoparticles in vivo, a F1-V loaded 
nanoparticle vaccine was delivered intranasally in a single-dose to convey 
protection against plague (Chapter 6). Results showed that a vaccine formulation 
of soluble F1-V co-delivered with F1-V loaded nanoparticles was able to maintain 
high-avidity antibody titers that correlated with complete protection against a 
lethal Yersinia pestis challenge at 6 or 23 weeks post-vaccination. The capacity 
for polyanhydride nanoparticles to induce near-term and long-lived protection 
provides a nanovaccine platform in which multiple parameters (polymer 
chemistry, particle size, antigen loading and delivery route) can be tailored to 
develop appropriate vaccine strategies against a wide array of infectious 
diseases. 
 
7.2 Future Work 
 
 The promising adjuvanticity of polyanhydride nanoparticles in vaccination 
against plague provide a basis for further research. While F1-V based 
vaccination conveyed protection, additional study into antigen modification and 
other protective Y. pestis antigens could yield products that lead to dose sparing 
and immunity against knock-out strains of bacteria designed to function as 
bioterrorism weapons. In addition, further nanoparticle optimization will lead to 
vaccine formulations that convey complete protection using the smallest dose 
possible. While the random copolymers currently being investigated hold great 
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promise, novel polyanhydride polymer and particle design could yield products 
with superior material properties and advanced delivery and/or adjuvanticity 
capacity. Finally, to better understand the intracellular behavior of internalized 
nanoparticles, new intracellular analytical tools must be developed. 
 
7.2.1  Yersinia pestis Vaccine Optimization 
 
 In order to enhance the immune response against F1-V, α-galactose 
modification of the antigen is being investigated. The α-galactose modification 
allows for immune processing of recombinant protein antigens more efficiently. 
Naturally occurring anti-α-galactose antibodies facilitate antigen processing by 
attaching to the modified antigen and facilitating uptake and processing by APCs 
through the Fcɣ receptor (Fig. 7.1a). The ability for this effect to induce enhanced 
antibody production against F1-V in vivo is shown in Fig. 7.1b. 
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(a) 
 
(b)
Figure 7.1. (a) APC processing and presenting of α-galactose modified F1-V. (b) 
Anti-F1-V IgG titers 40 days post-vaccination show that α-gal modification 
induced a superior immune response than the antigen alone. 
 
The enhancement of antibody production by α-gal modification has the capacity 
to significantly reduce vaccine dose and cost. 
 Also, identification of novel Y. pestis antigens could lead to the 
development of a multiple antigen vaccine that would convey protection to a 
heterogenous population of knock-out strains designed to circumvent current 
vaccine strategies. Three membrane proteins have been identified as possible 
alternative plague antigen candidates. Ail is involved in cell binding and cell 
invasion, LamB is involved in maltose metabolism and YapM is an 
autotransporter. These proteins are currently being purified and evaluated for 
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their ability to induce protective immune responses. If any of these are effective 
antigens they will be incorporated into nanoparticle based vaccines either as a 
single antigen or as a multiple antigen system to improve vaccination against 
wild-type and knock-out strains of Y. pestis.  
 
7.2.2 Nanoparticle Vaccine Optimization 
 
 While a vaccine formulation of soluble F1-V co-delivered with F1-V loaded 
50:50 CPTEG:CPH nanoparticles conveyed long-lived protection against plague, 
optimization of a number of parameters is necessary. 50:50 CPTEG:CPH 
nanoparticles induced promising DC activation in vitro, but only when compared 
to the other polymer chemistries (poly(SA), 50:50 CPH:SA, poly(CPH), and 
poly(CPTEG)) (Chapter 5).  Investigation of nanoparticles with finer chemistry 
differences may provide a better way to determine optimal copolymer chemistry. 
Approaching this by conventional synthesis and fabrication would be time-
consuming, but combinatorial methods allow for high-throughput analysis of a 
library of copolymer chemistries. Recent research by Petersen et al.3 shows that 
60:40 CPTEG:CPH may enhance cell surface marker expression more than 
50:50 CPTEG:CPH nanoparticles (Fig. 7.2). 
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Figure 7.2. Cell surface marker expression (mean fluorescence intensity (MFI)) 
as represented graphically of MHC II, CD209, CD86, CD40 and MHC I upon a 48 
h incubation of combinatorially fabricated CPH:SA and CPTEG:CPH 
nanoparticles with DCs. NS: non-stimulated cells (negative control) and LPS 
(200ng/mL) (positive control). Error bars represent standard error and minimum 
n=3. 
 
CPTEG-rich nanoparticles cannot be reproducibly fabricated at this time, but 
future research could create nanoparticles between 50:50 CPTEG:CPH and 
poly(CPTEG) that would be stable and optimal for immune activation. 
 It was determined that encapsulation of 20% of the total F1-V protein 
within nanoparticles resulted in superior antibody production and protection over 
0% and 100% encapsulation, but no other antigen encapsulation percentages 
were evaluated. Since the results described in this thesis have shown that an 
antigenic bolus and encapsulated payload are both required to initiate a long-
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lasting protective response, there must exist a continuum in which an optimal 
antigen encapsulation percentage can be determined (Fig. 7.3). 
 
 
Figure 7.3. Potential schematics for antibody response as a function of antigen 
encapsulation percentage. The blue curve shows high soluble antigen, the green 
curve shows high encapsulated antigen, and the red curve shows a relatively 
equal mix of soluble and encapsulated antigen as the best formulation. The black 
line represents the minimum response necessary for protection. 
 
Currently, it is unknown which profile best fits this continuum. Experiments 
varying antigen encapsulation percentage and monitoring the antibody response 
and protection capacity would allow tuning of nanoparticle adjuvanticity. In 
addition, the ability to reduce total antigen dose is dependent on this profile as 
shown in Fig. 7.4. 
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Figure 7.4. As total antigen dose is reduced (dashed lines), protective 
formulation range narrows and is dependent on the antigen encapsulation 
continuum. 
 
Variation of both antigen encapsulation percentage and total antigenic dose 
would allow for utilization of the lowest antigenic dose possible reducing vaccine 
cost. 
 Current research has analyzed the vaccine adjuvant and delivery capacity 
of particles composed of a single polymer chemistry of a given size. A logical 
next step is to investigate the possibility of combination vaccines with 
nanoparticles of varying chemistry and size. While it has been shown that 
recombinant proteins encapsulated within CPH:SA particles undergo significant 
degradation upon release4, the capacity for CPH:SA nanoparticles to enhance 
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monocytic uptake of soluble antigen (Chapter 4) may make blank CPH:SA 
nanoparticles promising candidates to adjuvant the soluble protein dose. Also, 
the DC stimulation profile and intracellular trafficking of CPH:SA nanoparticles 
was different than the 50:50 CPTEG:CPH nanoparticles (Chapter 5). The in vivo 
adjuvanticity mechanism(s) of CPH:SA nanoparticles may be significantly 
different than CPTEG:CPH nanoparticles. While nanoparticles have shown 
promise of depositing into deep lung tissue, the ability to create an antigen depot 
may improve vaccine effectiveness. Intranasally administered antigen loaded 
50:50 CPTEG:CPH microparticles would  settle in the nasal cavity and may be 
able to facilitate more gradual antigen delivery. By investigating cocktails of 
micropaticles and nanoparticles of varying chemistries, a vaccine system could 
be designed with enhanced properties over 50:50 CPTEG:CPH nanoparticles 
alone. 
 While intranasal delivery holds many advantages, cocktail vaccines may 
facilitate the best response by delivery through multiple routes. Microparticle 
antigen depots may function better in continual delivery if injected 
subcutaneously rather than residing in the nasal cavity. Heterologous delivery of 
prime-boost plague vaccination has shown promise over homologous delivery5, 
so replicating this for single-round delivery of particle-based vaccines may 
increase effectiveness. 
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7.2.3 Novel Polymer & Particle Design 
 
 While CPH:SA and CPTEG:CPH random copolymer particles function as 
promising nanovaccine adjuvants, advancements in polymer development and 
particle design could lead to materials with superior properties and delivery 
capabilities. So far research has focused on a copolymer continuum of chemistry 
going from poly(SA) to poly(CPH) to poly(CPTEG) (Fig. 7.5 top). By investigating 
terpolymers consisting of a combination of CPH, SA and CPTEG monomers (Fig. 
7.5 bottom), novel chemistries with enhanced material properties may be 
identified. 
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Figure 7.5. Current copolymer continuum (top) and terpolymer ternary 
composition diagram (bottom). 
 
The acidity of SA monomer makes it undesirable in high composition, but its 
proccessability makes it an attractive candidate if used in low composition. With 
current limitations in CPTEG-rich particle fabrication, further research into 
CPTEG-rich, CPH-poor, SA-poor (yellow area in Fig. 7.5 bottom) terpolymers 
may yield polyanhydrides with desirable antigen stabilizing capacity that can be 
reproducibly fabricated into stable nanoparticles. Due to the addition of another 
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variable, polymer and particle development for terpolymers lends itself to 
combinatorial evaluation. 
 While nanoparticles as small as 80 nm have been fabricated by 
antisolvent nanoprecipitation, smaller particles may have enhanced vaccine 
delivery effects. Recent research shows 25 nm particles are able to traffic directly 
through lymphatic vessels to draining lymph nodes6 and are trafficked 
intracellularly through a novel, non-degradative pathway.7 Enhanced design of 
polyanhydride nanoparticles could be realized by the synthesis of triblock 
copolymers. A possible schematic for this synthesis is outlined in Scheme 7.1. 
 
 
Scheme 7.1. Synthesis of triblock polyanhydride copolymers with 
ethylenediamine linkers 
 
By utilizing a reactive linker, high purity triblock polymers consisting of 
polyanhydrides can be synthesized. While any polymer blocks could be chosen 
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with this scheme, the protein stabilization capacity of poly(CPTEG) and the ability 
to maintain structure through gradual surface erosion of poly(CPH) and poly(SA) 
makes them excellent candidates for internal and external blocks, respectively.  
By choosing blocks of significantly different chemistry self assembly or 
precipitation in the correct solvent would cause the formation of a core-shell 
particles in which vaccines could be loaded into the core (poly(CPTEG)) and 
shells (poly(CPH)) would allow for long-term particle structure to be maintained 
(Fig. 7.6a). 
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(a) 
 
 (b) 
 
 (c) 
 
Figure 7.6. Triblock fabrication potential for (a) core-shell nanoparticles, (b) 
spotted core-shell nanoparticles, and (c) modified spotted core-shell 
nanoparticles.  
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While the design of single triblock core-shell nanoparticles is novel and holds 
promise, further engineering could yield the design of nanoparticles with unique 
functions. Triblocks with poly(CPH-b-CPTEG-b-CPH) and poly(SA-b-CPTEG-b-
SA) mixed together could create unique surface architectures (Fig. 7.6b). By 
having a small amount of poly(SA-b-CPTEG-b-SA) by composition to poly(CPH-
b-CPTEG-b-CPH), a segregation effect can occur to create spotted core-shell 
nanoparticles similar to those developed by Christian et al.8 Spot size can be 
tailored by composition and molecular weight to yield a size that could interact 
with receptors on desired cells like APCs. By first conjugating moieties (e.g., 
carbohydrates or small peptides) to the ends of poly(SA-b-CPTEG-b-SA) 
triblocks before particle fabrication (Fig. 7.6c), spotted core-shell nanoparticles 
could be synthesized with specificity for certain cell receptors in order to facilitate 
targeted delivery. Carrillo-Conde and co-workers have already shown the 
capacity for randomly distributed surface carbohydrate-modified nanoparticles to 
induce enhanced DC activation9, so confinement to specific spots on the particle 
surface has the potential to enhance this effect. 
 Another route for the design of novel polyanhydride nanoparticles is 
microemulsion polymerization. This process allows for the synthesis of polymer 
and formation of nanoparticles to occur in a single step. For this process, 
anhydride momomers are methacrylated as shown in Fig 7.7. 
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Figure 7.7. Chemical structures of (top) methacrylated SA, (middle) 
methacrylated CPH, and (bottom) methacrylated CPTEG. 
 
Methacrylation allows for the use of reversible addition-fragmentation chain 
transfer polymerization within microemulsions to synthesize nanoparticles. The 
microemulsion polymerization process is shown in Fig. 7.8.  
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Figure 7.8. Fabrication of nanoparticles by microemulsion polymerization where 
M = monomer, I = initiator, and P = polymer. (Reprinted from O’Donnell & 
Kaler10) 
 
Recent research with RAFT microemulsion polymerization of mSA yielded the 
fabrication of ultra small nanoparticles (<100 nm) (Fig 7.9). 
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Figure 7.9. Scanning transmission electron micrograph of mSA ultra small 
nanoparticles synthesized by microemulsion polymerization. Scale bar = 1 µm. 
 
The possibility to create nanoparticles with controlled size for vaccine delivery 
could be realized by this technique. 
 
7.2.4 Novel Intracellular Quantification Tools 
 
 Although we have exceptional capabilities to utilize fluorescent microscopy 
to monitor intracellular trafficking of polyanhydride nanoparticles, there exist 
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limitations to current experimental designs and techniques. In our current work, 
we have used a fluorescently labeled payload that acts as a reporter for 
nanoparticles. Also, only fluorescent material that is encapsulated can be easily 
visualized with microscopy. This constraint prevents the ability to accurately link 
the data generated by fluorescent microscopy to other experiments. By 
developing novel environmentally-sensitive fluorescent materials these limitations 
can be overcome. One potential solution is to develop conjugated quantum dots 
(QDs) that have fluorescence resonance energy transfer (FRET) sensitive to 
environmental conditions. A reactive QD of interest would be one that can 
modulate emission within biologically-relevant pH (4 to 8). A proposed system 
using a pH-responsive polymer linker between a QD and organic fluorescent dye 
is shown in Fig. 7.10. 
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Figure 7.10. Cartoon detailing a potential pH-sensitive QD. Poly((diethylamino 
ethyl) methacrylate) (pDEAEM) has been shown to be a pH-response 
polymer.11,12 In high pH, the tertiary amine is non-protonated and the polymer is 
able to collapse on itself (top left). As pH drops tertiary amines become 
protonated causing the polymer to expand (middle right).  By tethering a QD to a 
fluorescent dye (red circle) by a pDEAEM chain we will be able to utilize FRET as 
a reporter for pH. Under high pH conditions, the QD and dye will be close enough 
physically to allow for FRET (top center) to proceed generating dye-dominant 
emission (top right). Under low pH conditions, pDEAEM will move the dye away 
from the QD (middle left) allowing for QD-dominant emission (middle center).  In 
between extreme conditions (bottom), we hope to have variable FRET which we 
can use to accurately determine local pH levels. 
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The advantage of this novel system is that the material properties of the linker 
can be modulated to specific applications whereas current environmentally-
sensitive QD-based FRET systems require the modulation of the fluorescent dye 
(i.e., alcohol protonation13) to cause a change in the extinction coefficient of the 
dye. These materials are normally very narrow in their pH-sensitive range and 
require extensive research to develop each FRET pair. Some modulations that 
could be attempted are the use of varying lengths of polymer, non-reactive 
incorporated subunits (i.e. ethylene glycol methyl methacrylate), multiple cationic 
polymers, or even multiple fluorescent dyes. 
After conjugated QDs are fabricated that have desirable pH-sensitive 
FRET, they can be encapsulated within polyanhydride nanoparticles. Within 
nanoparticles, conjugated QDs should have collapsed linkers allowing for 
significant FRET to occur.  As nanoparticles release payload within acidic 
vesicles of APCs, the pDEAEM linker of conjugated QDs should become 
protonated and extend. In addition, individual QDs are visible with fluorescent 
microscopy making them excellent candidates to replace the fluorescent dyes 
being used currently. This characteristic can be exploited to identify encapsulated 
versus non-encapsulated QDs giving us additional insight into APC processing of 
nanoparticles. 
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